[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

US20060030565A1 - Amide derivatives and nociceptin antagonists - Google Patents

Amide derivatives and nociceptin antagonists Download PDF

Info

Publication number
US20060030565A1
US20060030565A1 US11/145,169 US14516905A US2006030565A1 US 20060030565 A1 US20060030565 A1 US 20060030565A1 US 14516905 A US14516905 A US 14516905A US 2006030565 A1 US2006030565 A1 US 2006030565A1
Authority
US
United States
Prior art keywords
methyl
amino
quinolyl
benzamide hydrochloride
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/145,169
Inventor
Hisashi Shinkai
Takao Ito
Hideki Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Priority to US11/145,169 priority Critical patent/US20060030565A1/en
Publication of US20060030565A1 publication Critical patent/US20060030565A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C07D219/08—Nitrogen atoms
    • C07D219/10—Nitrogen atoms attached in position 9
    • C07D219/12—Amino-alkylamino radicals attached in position 9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to a nociceptin antagonist containing a novel amide derivative or a pharmaceutically acceptable salt thereof. More particularly, the present invention relates to an analgesic containing,-as an active ingredient, a novel amide derivative or a pharmaceutically acceptable salt thereof, which show analgesic effect as nociceptin antagonist by selectively acting on an opioid receptor like-1 receptor and which are useful for the treatment of pain, particularly sharp pain or pain caused by sensory nerve abnormality, such as hyperalgesia and allodynia.
  • the present invention moreover relates to a novel use of a certain kind of amide derivative as a nociceptin antagonist and analgesic.
  • Analgesics are divided into central analgesic and peripheral analgesic according to the main action site thereof.
  • the cause of pain is a complicated entanglement of autonomic nerve reactions, feeling and the like, sedative, antianxiety, antidepressant, hypnotic, antispasmodic, vasodilator and the like are used as analgesic auxiliary agents.
  • Central analgesics are roughly divided into narcotic analgesic, anarcotic analgesic and-antipyretic analgesic.
  • Narcotic and anarcotic opioids have been used for the treatment of sharp pain such as postoperative pain and myocardial infarction, burn and the like. These analgesics show noticeable effects resulting from a strong analgesic action combined with an action to remove fear of pain.
  • narcotic analgesics accompany physical dependence and mental dependence and express withdrawal syndrome by drug dependence. Other side effects of respiratory suppresion, nausea, emesis, constipation, dysuria and the like restrict their use.
  • Antipyretic analgesic is effective for superficial pain, such as toothache, myalgia and the like, but is considered to be ineffective for visceralgia. Its antipyretic action is considered to focus on hypothalamus thermoregulation center, and analgesic action is mainly exerted via peripheral nerves. However, there are many unknown parts in the central action mechanism thereof. Its analgesic effect is generally weaker than that offered by narcotic and anarcotic opioids. Consequently, sharp pain is cautiously treated with narcotic and anarcotic opioids in clinical situations to the extent that causes less side effects.
  • Certain pain caused by injury and functional disorder of nerves and the like is resistant to analgesics currently in clinical use, such as antipyretic analgesic and narcotic analgesic, and shows no significant analgesic effect.
  • analgesic particularly a strong analgesic free from addiction and an analgesic to treat pain caused by sensory nerve abnormality such as hyperalgesia, allodynia and the like.
  • Pain is caused when an algesic substance, which is released upon occurrence of tissue disorder due to nociceptive stimulus (chemical stimulus, mechanical stimulus, thermal stimulus), excites nociceptor (free nerve terminal) at the sensory nerve terminal, and the information of the pain sensation reaches the cerebral cortex and is recognized as pain.
  • nociceptive stimulus chemical stimulus, mechanical stimulus, thermal stimulus
  • nociceptor free nerve terminal
  • visceralgia is considered to be caused by the contraction of visceral smooth muscle, that mechanically extends and excites the sensory nerve.
  • Pain sensation is mostly transmitted by two kinds of thin nerve fiber A ⁇ and C fibers, wherein sharp mechanical stimulus conducts myelinated A ⁇ fiber and dull pain conducts unmyelinated C fiber.
  • Typical algesic substance includes bradykinin, serotonin, histamine and the like, that act on nociceptor at the nerve terminal.
  • Such pain afferent fiber primary afferent fiber
  • the primary afferent fiber excites nociceptive neuron via neurotransmitters, such as excitatory amino acid, substance P and the like, and the information is transmitted from dorsicornu to medulla oblongata, thalamus and to cerebral cortex.
  • neurotransmitters such as excitatory amino acid, substance P and the like
  • Pressure and tactile sensation is mainly transmitted by thicker A ⁇ fiber which transmits the information from sensory nerve terminal to dorsicornu, medulla oblongata, thalamus and to cerebral cortex, like pain afferent fiber.
  • Opioid receptors involved in algesia exist in various parts of these spinothalamic tracts.
  • the respiratory suppressive action, nauseant action and the like result from the action on the opioid receptor in the medulla oblongata.
  • opioid acts on spinal cord, medulla oblongata, thalamus and cerebral cortex to show strong analgesic effect suppression of thalamus and cerebral cortex is not its main action.
  • Direct suppression of opioid receptor in the dorsicornu neuron and suppression of dorsicornu neuron by descending depression via midbrain and medulla oblongata are considered to be the main action.
  • Tactile sensation tends to be dull upon sustained application of stimuli of the same intensity.
  • This adaptation is unfeasible in case of pain, but sustained release of neurotransmitter by long-term stimulation of sensory nerve is considered to induce chronic pain by changing the excitatory or information transmission efficiency of the nerve cell.
  • inhibitory neurotransmitters such as ⁇ -aminobutyric acid (GABA), glycine and the like, suppress excitement of nerves upon activation of each receptor. While allodynia is considered to be partly induced by dull suppression of neurotransmission due to the stimuli repeatedly applied to the sensory nerve, the mechanism of the onset of chronic pain, hyperalgesia and allodynia has been known only to a limited degree.
  • the sensory nerve transmission is controlled by excitatory nerve fiber and inhibitory nerve fiber in complicated relationship with each other, and many neurotransmitters involved therein have been found to exist.
  • a pharmaceutical agent exhibiting effective analgesic action.
  • enkephalin which is an endogenous pentapeptide having analgesic effect
  • enkephalin which is an endogenous pentapeptide having analgesic effect
  • opioids inclusive of morphine act on opioid receptor.
  • the opioid receptor is known to include several subtypes, wherein morphine shows high affinity for ⁇ receptor, enkephalin shows high affinity for ⁇ receptor and dynorphin shows high affinity for ⁇ receptor, these consisting the base thereof.
  • ORL-1 An opioid receptor like-1 (ORL-1) receptor has high homology with opioid receptor but does not bind with conventional opioid ligands. This receptor was cloned in 1993.*1*2 In 1995, peptide consisting of 17 amino acids was isolated as endogenous ligand of ORL-1 receptor, and structurally characterized and named Nociceptin or Orphanin FQ *3*4 (*1; FEBS Lett., 341, 33-38, 1994) (*2; FEBS Lett., 347, 284-288, 1994) (*3; Nature, 377, 532-535, 1995) (*4; Science, 270, 792-794, 1995).
  • nociceptin is similar to that of Dynorphin A which is an endogenous opioid peptide.
  • Dynorphin A is a ⁇ receptor agonist showing analgesic effect, but binds weakly with ORL-1 receptor and is said to have no activity*5.
  • Nociceptin binds extremely weakly with an opioid receptor*6, and algesia tests including hot plate test*7 using mouse, scratching of lower abdomen with both hindlimbs of mouse, biting and licking of both hindlimbs (SBL) behavior induction test*8 and the like have revealed its promoting action on transmission of pain information.
  • nociceptin and ORL-1 receptor had specific affinity for each other, and nociceptin was a peptide that induced or amplified pain, conversely from the case of opioid peptide.
  • the study of action mechanism thereof is underway. (*5; Eur. J. Pharmacol., 321, 97, 1997) (*6; J. Biol. Chem., 271, 23642, 1996) (*7; Anesthesia, 45, 1060-1066,1996) (*8; 18 th Analgesic, Opioid Peptide Symposium Abstract, 11-14, 1997).
  • ORL-1 receptor has been reported to express more in the central nerve system, such as cerebral cortex, hypothalamus, spinal cord and the like*9, and nociceptin has been shown to be distributed more on the surface layer of dorsicornu where primary pain afferent fiber terminates*10, and algesia transmission of nociceptin is considered to be mainly through central nerve system (*9; J. Neurochemistry, 64, 34-40, 1995) (*10; Neuro Report 7, 3021-3025, 1996).
  • nociceptin induces nociceptive hypersensitivity (hyperalgesia*3*4, allodynia*11) and that it amplifies excitatory stimulus by heat and tactile (*11; Molecular Brain Research, 43, 96-104, 1996).
  • nociceptin antagonistic action is only nociceptin-like polypeptide and naloxone benzoylhydrazone which is a ⁇ receptor antagonist having a morphine-like structure, both of which having ORL-1 receptor affinity, and a pharmaceutical agent having specific antagonistic action on ORL-1 receptor has not been developed.
  • analgesic having a quinoline skeleton includes opioid or anesthetic antagonist analgesic [Japanese Patent Unexamined Publication No. 63-264460 (EP 277794; BOC Inc.)], analgesic having a different action mechanism [Japanese Patent Unexamined Publication No. 62-503030 (U.S. Pat. No. 5,104,884; Alkaloida Vegyeszeti Gyar, antifungal action), WO96/13485 (EP 807105; Fujisawa Pharmaceutical Industries, Ltd., bradykinin antagonist), WO96/11930 (Smithkline beecham P.L.C., serotonin receptor antagonist), Japanese Patent Unexamined Publication No.
  • a pharmaceutical agent having nociceptin antagonistic action can make an effective agent for pain, particularly sharp pain such as postsurgery pain and the like or pain caused by sensory nerve abnormality, such as hyperalgesia, allodynia and the like, and a safe pharmaceutical agent showing selective action on ORL-1 receptor and free of marked side effects.
  • the present invention now provides a hovel compound having an analgesic effect.
  • the present invention specifically provides the following (1) to (20).
  • R 1 and R 2 are the same or different and each is hydrogen atom, lower alkyl optionally substituted by hydroxy, amino, lower alkylamino or di(lower)alkylamino;
  • R 3 and R 4 are the same or different and each is hydrogen atom, halogen atom or lower alkyl
  • ring A is aryl or heterocyclic group
  • ring B is phenyl, thienyl, furyl, pyrrolyl, pyrrolidinyl, oxazolyl or cyclohexenyl;
  • X is hydrogen atom, halogen atom, lower alkyl optionally substituted by lower alkoxy, lower alkenyl, amino, cyano or a group of the formula
  • E is a single bond, carbonyl, sulfinyl, —O—, —S—, —NHCO—, —CH ⁇ CR 6 — wherein R 6 is hydrogen atom or aryl or —NR 7 — wherein R 7 is hydrogen atom, lower alkyl or lower alkoxycarbonyl;
  • ring G is aryl, heterocyclic group, cycloalkyl or condensed aryl
  • R 5 is halogen atom, hydroxy, lower alkyl Optionally substituted by any of halogen atom, hydroxy, lower alkanoyloxy and lower alkoxy optionally substituted by lower alkoxy, lower alkoxy optionally substituted by lower alkoxy, amino, lower alkylamino, di(lower)alkylamino, nitro, cyano, lower alkanoyl, lower alkanoyloxy,
  • t is 0 or an integer of 1 to 5, which indicates
  • n is 0 or an integer of 1 to 8.
  • n is 0 or an integer of 1 to 4, or a pharmaceutically acceptable salt thereof as an active ingredient.
  • E, ring G, R 5 , t, m and n are as defined in (1), or a pharmaceutically acceptable salt thereof as an active ingredient.
  • R 8 is lower alkylthio, or a pharmaceutically acceptable salt thereof as an active ingredient.
  • R 2 , ring B, E, ring G, R 5 , t, m and n as defined in (1), or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition comprising the amide derivative of any of (5) to (9) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • a nociceptin antagonist containing the amide derivative of any of (5) to (9) or a pharmaceutically acceptable salt thereof as an active ingredient is provided.
  • a method for expressing a nociceptin antagonistic action comprising administering the amide derivative of any of (1) to (9) or a pharmaceutically acceptable salt thereof.
  • a method for treating pain comprising administering the amide derivative of any of (1) to (9) or a pharmaceutically acceptable salt thereof.
  • a pharmaceutical composition for antagonizing nociceptin which comprises the amide derivative of any of (1) to (9) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • a commercial package comprising the pharmaceutical composition of (17) and a written matter associated therewith, the written matter stating that the pharmaceutical composition can be or should be used for antagonizing nociceptin.
  • a pharmaceutical composition for analgesic use which comprises the amide derivative of any of (1) to (9) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • a commercial package comprising the pharmaceutical composition of (19) and a written matter associated therewith, the written matter stating that the pharmaceutical composition can be or should be used for analgesia.
  • Halogen atom is fluorine atom, chlorine atom, bromine atom or iodine atom. At R 3 , R 4 , R 5 and R 5′′ , it is preferably chlorine atom.
  • Lower alkyl has linear or branched chain and 1 to 6 carbon atoms. Specific examples thereof include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, tert-pentyl, hexyl and the like.
  • R 3 , R 4 , R 7 , R 9 , R 10 , R 11 and R 2′ it is more preferably methyl and at R 5′ , it is more preferably methyl or ethyl.
  • Lower alkoxy has an alkyl moiety defined above as lower alkyl. Specific examples include methoxy, ethoxy, propoxy, isopropyloxy, tert-butoxy and the like.
  • Lower alkylthio has an alkyl moiety defined above as lower alkyl. Specific examples include methylthio, ethylthio, propylthio, isopropylthio, tert-butylthio and the like.
  • its alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms.
  • R 8 it is more preferably methylthio.
  • Lower alkanoyl has an alkyl moiety defined above as lower alkyl. Specific examples include acetyl, propionyl, butyryl, isobutyryl, pivaloyl and the like.
  • its alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms.
  • R 5 it is more preferably acetyl.
  • Lower alkylsulfonyl has an alkyl moiety defined above as lower alkyl. Specific examples include mesyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, tert-butylsulfonyl and the like.
  • its alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms.
  • R 5 it is more preferably mesyl.
  • Lower alkanoyloxy has an alkyl moiety defined above as lower alkyl. Specific examples include acetoxy, propionyloxy, butyryloxy, isobutyryloxy, pivaloyloxy and the like.
  • its alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms.
  • R 5 it is more preferably acetoxy.
  • Lower alkoxycarbonyl has an alkyl moiety defined above as lower alkyl. Specific examples include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropyloxycarbonyl, tert-butoxycarbonyl and the like.
  • its alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms.
  • R 5 it is more preferably methoxycarbonyl
  • R 7 it is more preferably tert-butoxycarbonyl.
  • Lower alkyl optionally substituted by hydroxy means that the above-defined lower alkyl is optionally substituted by one or more hydroxy, and that the lower alkyl may be unsubstituted. Specific examples include methyl, ethyl, propyl, isopropyl, hydroxymethyl, 1,2-dihydroxyethyl, 2-(hydroxymethyl)butyl and the like.
  • R 1 and R 2 are preferably methyl, ethyl, propyl, isopropyl or hydroxymethyl, and more preferably methyl or ethyl.
  • Lower alkyl optionally substituted by lower alkoxy means the above-defined lower alkyl optionally substituted by the above-defined lower alkoxy, including unsubstituted alkyl. Specific examples include methyl, ethyl, methoxymethyl, ethoxymethyl, 2-(methoxymethyl)butyl and the like.
  • its base alkyl moiety is a linear alkyl having 1 to 4 carbon atoms.
  • X it is more preferably methoxymethyl.
  • Lower alkoxy optionally substituted by lower alkoxy means the above-defined lower alkoxy optionally substituted by the above-defined lower alkoxy, including unsubstituted alkoxy. Specific examples include methoxy, ethoxy, methoxymethoxy, methoxyethoxy, 2-(methoxymethyl)butyloxy and the like.
  • its base alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms.
  • R 5 it is more preferably methoxy or methoxymethoxy.
  • Lower alkyl optionally substituted by any of halogen atom, hydroxy, lower alkanoyloxy and lower alkoxy optionally substituted by lower alkoxy means that the above-defined lower alkyl is optionally substituted by one or more of the above-defined halogen atom, hydroxy, the above-defined lower alkanoyloxy and the above-defined lower alkoxy optionally substituted by lower alkoxy, each of which may be the same or different, and that the lower alkyl may be unsubstituted.
  • Specific examples include methyl, ethyl, propyl, isopropyl, tert-butyl, hydroxymethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, acetoxymethyl, pivaloyloxymethyl, bromomethyl, trifluoromethyl, methoxymethoxymethyl, methoxyethoxymethyl and the like.
  • its base alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms.
  • R 5 it is more preferably methyl, ethyl, propyl, isopropyl, tert-butyl, hydroxymethyl, acetoxymethyl, trifluoromethyl or methoxymethoxymethyl and more preferably ethyl.
  • Lower alkylamino is a monoalkylamino group wherein the alkyl moiety is defined above as lower alkyl. Specific examples include methylamino, ethylamino, propylamino, isopropylamino, tert-butylamino and the like.
  • its alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms.
  • R 1 and R 2 it is more preferably methylamino.
  • Di(lower)alkylamino is a dialkylamino group wherein the alkyl moiety is the same or different and as defined above as lower alkyl. Specific examples include dimethylamino, diethylamino, methylethylamino, N-isopropyl N-isobutylamino and the like.
  • its alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms.
  • R 1 , R 2 and R 5 it is more preferably dimethylamino.
  • Lower alkenyl is linear chain alkenyl having 1 to 6 carbon atoms. Examples thereof include vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, 2,4-butadienyl, 1-pentenyl, 1,3-pentadienyl and 1,3,5-hexatrienyl and the like.
  • X is preferably vinyl.
  • Aryl is an aromatic hydrocarbon group having 6 to 18 carbon atoms. Examples thereof include phenyl, naphthyl, anthryl, indenyl, azulenyl, fluorenyl, phenanthryl, pyrenyl and the like.
  • Ring A is preferably phenyl and naphthyl, more preferably phenyl.
  • Ring G and R 6 are preferably phenyl.
  • substituent R 5 is preferably bonded at para-position.
  • Heterocyclic ring is a cyclic compound group having one or more from oxygen atom, nitrogen atom and sulfur atom as hetero atom, wherein plural hetero atoms may be contained and the number of atoms constituting the ring is 5 to 20.
  • Specific examples thereof include pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, quinolyl, isoquinolyl, indolyl, benzofuranyl, benzimidazolyl, imidazolidinyl, indolinyl, pyrrolidinyl, pyrolinyl, piperidinyl, piperazinyl, chromanyl, morpholinyl, phthalazinyl, naphthyridinyl, quinazolinyl, quinoxalyl, cinnolinyl, pter
  • Ring G is preferably pyridyl, benzofuranyl or 2,3-dihydrobenzofuranyl, more preferably 2,3-dihydrobenzofuranyl.
  • Ring A is preferably a cyclic compound group containing one or more nitrogen atoms as hetero atoms, and the number of atoms constituting the ring is 9 to 14. More preferably, it is quinolyl, isoquinolyl, quinoxalyl, benzimidazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroacridinyl or 2,3-dihydro-1H-cyclopenta[b]quinolyl, most preferably quinolyl, 5,6,7,8-tetrahydroacridinyl or 2,3-dihydro-1H-cyclopenta[b]quinolyl.
  • R 1 be an amino group substituting at the 4-position
  • R 2 be a lower alkyl substituting at the 2-position and —NHCO— substitute at the 6-position.
  • Cycloalkyl is a saturated cycloalkyl having 3 to 8 carbon atoms, which is exemplified by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cycloctyl.
  • Ring G is preferably cyclohexyl.
  • Condensed aryl is the above-defined aryl wherein the above-defined cycloalkyl groups are condensed, which is a cyclic compound-group wherein the number of atoms constituting the ring is 5 to 18. Specific examples include indanyl, 5,6,7,8-tetrahydro-2-naphthyl, 5,6,7,8-tetrahydro-3-naphthyl, 12,3,4-tetrahydro-2-naphthyl, 5.6,7,8-tetrahydro-2-anthryl, 1,2,3-trihydroazulenyl and the like.
  • Ring G is preferably 5,6,7,8-tetrahydro-2-naphthyl.
  • Protected amino is an amino group protected by an amino-protecting group used in a typical chemical synthesis.
  • Specific examples of the amino-protecting group include formyl, acetyl, benzoyl, benzyloxycarbonyl, methoxycarbonyl, tert-butoxycarbonyl, phthaloyl, benzyl, tosyl and the like.
  • Carboxy-protecting group is a carboxy-protecting group used in a typical chemical synthesis. Specific examples thereof include methyl, methoxyethoxymethyl, phenacyl, phthalimidomethyl, ethyl, 2,2,2-trichloroethyl, 2-methylthioethyl, tert-butyl, benzyl, p-nitrobenzyl, p-methoxybenzyl, tert-butyldimethylsilyl and the like.
  • Hydroxy-protecting group is a hydroxy-protecting group used in a typical chemical synthesis. Specific examples thereof include trimethylsilyl, tert-butyldimethylsilyl, methyl, benzyl, p-methoxybenzyl, tert-butyl, trityl, tetrahydropyranyl, methoxymethyl, methoxyethoxyethyl, acetyl, benzoyl and the like.
  • each symbol preferably means the following.
  • Ring G is preferably aryl.
  • R 5 is preferably halogen atom; lower alkyl optionally substituted by any of halogen atom, hydroxy, lower alkanoyloxy and lower alkoxy optionally substituted by lower alkoxy; lower alkoxy optionally substituted by lower alkoxy; nitro; cyano; or lower alkanoyl, and more preferably lower alkyl optionally substituted by any of halogen atom, hydroxy, lower alkanoyloxy and lower alkoxy optionally substituted by lower alkoxy.
  • the t is preferably O or an integer of 1 or 2, more preferably 1.
  • the E is preferably a single bond or —O—, more preferably —O—.
  • n is preferably 0.
  • E is —O—
  • m is preferably an integer of 1 to 7, lo more preferably 1
  • n is preferably 0.
  • E is a single bond
  • m+n is preferably 2.
  • the compound of the formula [1] includes various isomers. For example, there exist geometric E- and Z-isomers. When asymmetrical carbon atom(s) exist(s), stereoisomers (e.g., enantiomer and diastereomer) exist. Depending on the case, tautomers may exist in the present invention. Therefore, the present invention encompasses all these isomers and mixtures thereof.
  • the pharmaceutically acceptable salt thereof may be any salt as long as it can form a nontoxic salt with the compound of the above-mentioned formula (1], [1′] or [1′′].
  • examples thereof include salts with inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like; salts with organic acid such as oxalic acid, malonic acid, citric acid, fumaric acid, lactic-acid, malic acid, succinic acid, tartaric acid, acetic acid, gluconic acid, ascorbic acid, methylsulfonic acid, benzylsulfonic acid and the like; salts with inorganic base such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, ammonium hydroxide and the like; salts with organic base such as methylamine, diethylamine, triethylamine, triethanolamine, ethylenediamine, tris(hydroxymethyl)methylamine, guanidine, cho
  • the present invention further encompasses prodrugs and metabolites of each compound.
  • Prodrug is a derivative of the compound of the present invention, which has a chemically or metabolically decomposable group and which shows efficacy upon restoration to its original form after administration to a body, wherein included therein are a complex without a covalent bond and salts.
  • the compound of the present invention When used as a pharmaceutical preparation, it is generally admixed with conventionally known pharmaceutically acceptable carrier, excipient, diluent, extender, disintegrator, stabilizer, preservative, buffer, emulsifier, aromatic, coloring agent, sweetener, tackifier, flavor, solubilizer and other additive, specifically water, vegetable oil, alcohol (e.g., ethanol, benzyl alcohol and the like), polyethylene glycol, glycerol triacetate, gelatin, carbohydrate (e.g., lactose, starch and the like), magnesium stearate, talc, lanolin, petrolatum and the like, and formulated into tablets, pills, powders, granules, suppositories, injections, eye drops, liquids, capsules, troches, aerosols, elixirs, suspensions, emulsions, syrups and the like by a conventional method, which can be administered systemically or locally by oral or parenteral
  • the dose varies depending on age, body weight, symptom, therapeutic effect, administration route and the like, it is generally 0.01 mg to 1 g per dose which is given once to several times a day for an adult.
  • the treatment of reaction may be a conventional one, such as isolation and purification, crystallization, recrystallization, silica gel column chromatography, preparative HPLC and the like, which may be appropriately selected and combined.
  • a protecting group may be introduced into a functional group and deprotected for production.
  • ring A is a quinoline ring
  • the quinoline synthetic method of Camps the quinoline synthetic method of Combes, the quinoline synthetic method of Friedlander, the quinoline synthetic method of Knorr, the quinoline synthetic method of Niementowski and the like can be used for synthesis.
  • a part of the compound can be obtained as a commercially available reagent.
  • Compound [I-1] and compound [I-2] are condensed in an alcohol solvent, such as methanol, ethanol, n-propanol, isopropanol and the like, at room temperature or under heating to give compound [I-3].
  • an alcohol solvent such as methanol, ethanol, n-propanol, isopropanol and the like
  • Preferable solvent is diphenyl ether or a mixture of diphenyl ether and diphenyl such as Dowtherm A (trademark Fluka).
  • This production method can be applied to compound [I-1] wherein the ⁇ -position of ⁇ -keto acid ester is substituted by lower alkyl.
  • quinoline compound is obtained from isatin compound. wherein R 3 and Y are as defined above.
  • the following production method can be used to introduce a specific substituent or into a specific substitution site.
  • 4-hydroxy-2-methoxycarbonylquinoline compound is obtained from acetylenedicarboxylate compound and aniline compound.
  • the methoxycarbonyl group of this compound can be converted to hydroxymethyl group by reduction in a later step.
  • R 3 and Y are as defined above.
  • a typical reduction using tin or tin (II) chloride and conc. hydrochloric acid; alkaline metal sulfide such as aqueous sodium sulfide solution; catalytic reduction and the like may be used.
  • halogenating agent such as hypohalite (e.g., hypochlorite and the like), N-bromosuccinimide and the like can be used instead of bromine for halogenation.
  • Nitric acid or inorganic nitrate-sulfuric acid may be used instead of a mixture of nitric acid-sulfuric acid for nitration.
  • Step 3 is subjected to catalytic reduction using a hydrogenating catalyst in an alcohol solvent such as methanol, ethanol, n-propanol, isopropanol and the like by adding hydrochloric acid or hydrogen bromide-acetic acid solution at room temperature or under heating under normal pressure to high pressure to give compound [I-16].
  • a hydrogenating catalyst such as methanol, ethanol, n-propanol, isopropanol and the like by adding hydrochloric acid or hydrogen bromide-acetic acid solution at room temperature or under heating under normal pressure to high pressure to give compound [I-16].
  • hydrogenating catalyst examples include palladium carbon, palladium hydroxide, palladium black, Raney-nickel, platinum oxide and the like.
  • Step 1 Compound [I-18] obtained in Production method 1-5, Step 1 is subjected to dehydrogenation for a few days using Fremy's salt in 4% aqueous sodium carbonate solution at room temperature to give compound [I-19].
  • Step 2 is reacted with m-chloroperbenzoic acid in a halogen solvent, such as dichloromethane, chloroform, carbon tetrachloride and the like, at room temperature for N-oxidation to give compound [I-20].
  • a halogen solvent such as dichloromethane, chloroform, carbon tetrachloride and the like
  • Step 3 is reacted with phosphorus oxychloride in a hydrocarbon solvent, such as toluene, xylene and the like, under heating to give compound [I-21].
  • a hydrocarbon solvent such as toluene, xylene and the like
  • quinoline compound condensed with cycloalkyl is obtained by condensation of saturated cyclic ketone and anthranilonitrile compound.
  • Y is as defined above and p is 0 or an integer of 1.
  • An acid catalyst such as Lewis acid (e.g., zinc chloride) is added to a mixture of Compound [I-22] and compound [I-23] under heating for condensation to give compound [I-24].
  • Lewis acid e.g., zinc chloride
  • a substituent of a compound is substituted by amino group or substituted amino group.
  • ring A, R 2 , R 3 and Y are as defined above, R 9 is hydrogen-atom or lower alkyl and R 10 is lower alkyl.
  • dimethyl sulfate or methyl p-toluenesulfonate is used to introduce methoxy group in the scheme.
  • preferable solvent examples include hydrocarbon solvent such as benzene, toluene, hexane, xylene and the like; and ether solvent such as 1,4-dioxane, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran and the like.
  • metal alkoxide sodium methoxide is used and as the solvent, methanol is used as the corresponding alcohol solvent to introduce methoxy shown in the scheme.
  • the compound [I-25] in this Production method 1-7 may be compound [I-11] obtained in Production method 1-3.
  • conc. hydrochloric acid treatment heating in conc. ammonia, potassium hydroxide treatment and the like may be used.
  • Y is nitro
  • a typical method of conversion to amine by reduction of nitro is used.
  • compound [I-31] obtained in Production method 1-7 or commercially available reagent is subjected to catalytic reduction in a solvent at room temperature or under heating, at normal pressure or high pressure using a hydrogenating catalyst to give compound [I].
  • the solvent examples include ether solvent such as 1,4-dioxane, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran and the like; polar solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone and the like; alcohol solvent such as methanol, ethanol, propanol, butanol and the like; ester such as ethyl formate, ethyl acetate, butyl acetate and the like; water; or a mixed solvent thereof.
  • ether solvent such as 1,4-dioxane, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran and the like
  • polar solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone and the like
  • alcohol solvent such as methanol, ethanol, propanol, butanol and the like
  • ester such as
  • the hydrogenating catalyst is exemplified by palladium carbon, palladium hydroxide, palladium black, Raney-nickel, platinum oxide and the like.
  • methyl of a methyl-substituted carboxylic acid compound is converted to ether.
  • ring B, ring G, R 4 , R 5 and t are as defined above, and Z is a carboxy-protecting group.
  • the solvent examples include hydrocarbon solvent such as benzene, toluene, hexane, xylene and the like; ether solvent such as 1,4-dioxane, diethylether, 1,2-dimethoxyethane, tetrahydrofuran and the like; polar solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone and the like; and alcohol solvent such as methanol, ethanol, propanol, butanol and the like.
  • hydrocarbon solvent such as benzene, toluene, hexane, xylene and the like
  • ether solvent such as 1,4-dioxane, diethylether, 1,2-dimethoxyethane, tetrahydrofuran and the like
  • polar solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone and the like
  • alcohol solvent such as methanol, ethanol
  • compound [II-3] can be easily obtained as a commercially available reagent but a compound difficult to obtain can be synthesized by the following production methods.
  • a cyclic compound having a substituent is substituted by halogen atom.
  • ring G is as defined above, R 5′ is lower alkyl and R 5‘ is halogen atom.
  • the compound is halogenated in a halogen solvent, such as dichloromethane, chloroform, carbon tetrachloride, tetrachloroethylene and the like, to substitute chlorine atom at the ortho-position of 4-alkyl substituted phenol.
  • a halogen solvent such as dichloromethane, chloroform, carbon tetrachloride, tetrachloroethylene and the like
  • a cyclic compound is substituted by alkylsulfonyl.
  • ring G is as defined above, Q is a hydroxy-protecting group and R 11 is lower alkyl.
  • R 11 is methyl
  • aqueous hydrogen bromide is added and heated, or heated with sodium cyanide in dimethyl sulfoxide to allow deprotection.
  • benzofuran compound or 2,3-dihydrobenzofuran compound is synthesized from phenol compound. wherein Q is as defined above.
  • Compound [II-10] is condensed with compound [II-11] in a polar solvent, such as dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone and the like, in the presence of a base, such as potassium carbonate, sodium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium hydride, sodium hydride, potassium hydride and the like, under heating to give compound [II-12].
  • a polar solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone and the like
  • a base such as potassium carbonate, sodium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium hydride, sodium hydride, potassium hydride and the like
  • Step 1 is cyclized using an agent for condensation, such as polyphosphoric acid and the like, in a hydrocarbon solvent, such as benzene, toluene, hexane, xylene and the like, under heating to give compound [II-13].
  • an agent for condensation such as polyphosphoric acid and the like
  • a hydrocarbon solvent such as benzene, toluene, hexane, xylene and the like
  • the solvent examples include, besides alcohol solvents, ether solvents such as 1,4-dioxane, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran and the like and a mixed solvent thereof and the like.
  • a carboxy-protecting group is eliminiated from a compound. wherein ring B, R 4 , X and Z are as defined above.
  • the carboxy-protecting group can be eliminated by a conventional deprotection method depending on the kind of protecting group.
  • compound [II-16] when Z is methyl, compound [II-16] is reacted in an alcohol solvent, such as methanol, ethanol, n-propanol, isopropanol and the like, in the presence of a base, such as potassium carbonate, sodium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide and the like, under heating for-deprotection, and the resulting solution is acidified to give compound [II].
  • an alcohol solvent such as methanol, ethanol, n-propanol, isopropanol and the like
  • a base such as potassium carbonate, sodium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide and the like
  • amine compound and carboxylic acid compound are condensed to amine.
  • ring A, ring B, R 1 , R 2 , R 3 , R 4 and X are as defined above.
  • compound [II] is treated with a halogenating agent, such as oxalyl chloride, thionyl chloride, phosphorus oxychloride, phosphorus pentachloride and the like, in a solvent at room temperature to give the corresponding acid chloride. Then, the compound is condensed with compound [I] in the presence of a tertiary amine, such as triethylamine and the like, or pyridine at room temperature or under cooling to give compound [1].
  • a halogenating agent such as oxalyl chloride, thionyl chloride, phosphorus oxychloride, phosphorus pentachloride and the like
  • preferable solvent examples include halogen solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; ether solvents such as 1,4-dioxane, diethyl ether, 1,2-dimethaxyethane, tetrahydrofuran and the like.
  • halogen solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like
  • ether solvents such as 1,4-dioxane, diethyl ether, 1,2-dimethaxyethane, tetrahydrofuran and the like.
  • compound [I] and compound [II] are reacted in a solvent in the presence of an agent for condensation at room temperature to give compound [1].
  • an enhancer may be used for smooth reaction.
  • agent for condensation examples include N,N′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide, N,N′-diisopropylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and the like and examples of the enhancer include hydroxysuccinimide, 1-hydroxybenzotriazole and the like.
  • preferable solvent examples include a hydrocarbon solvent such as benzene, toluene, hexane, xylene and the like; a halogen solvent such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; an ether solvent such as 1,4-dioxane, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran and the like; a polar solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile and the like; and a mixed solvent thereof.
  • a hydrocarbon solvent such as benzene, toluene, hexane, xylene and the like
  • a halogen solvent such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like
  • an ether solvent such as 1,4-dioxane, diethy
  • the nitro group may be reduced after formation of amide by condensation, or when compound [I] and compound [II] have a functional group such as hydroxy and the like, deprotection may be carried out after formation of amide by condensation.
  • methoxycarbonyl-substituted compound obtained in Production method 1-3 and Production method 3 is added to-an ether solvent, such as 1,4-dioxane, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran and the like, and lithium tetrahydroborate is added by portions in an argon stream under cooling for reduction to give hydroxymethyl-substituted compound.
  • an ether solvent such as 1,4-dioxane, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran and the like
  • lithium tetrahydroborate is added by portions in an argon stream under cooling for reduction to give hydroxymethyl-substituted compound.
  • Methyl ⁇ -(p-acetamidophenylamino)crotonate (231.5 g, 0.93 mol) obtained in Preparation Example 1-1, Step 1 was added by small portions to Dowtherm A (trademark, 600 ml) which underwent refluxing under heating. The mixture was refluxed under heating for 10 minutes and the reaction mixture was cooled to room temperature. The resulting precipitate was collected by filtration and washed with ethyl acetate. The obtained crude crystals were suspended in methanol and collected by filtration to give N-(4-hydroxy-2-methyl-6-quinolyl)acetamide (178.3 g, 88%, deep yellow. crystals).
  • N-(4-Methoxy-2-methyl-6-quinolyl)acetamide (55.6 g, 0.24 mol) obtained in Preparation Example 1-1, Step 3 was mixed with ammonium acetate (279.4 g, 3.62 mol) and the mixture was stirred under heating at 135° C. for 4 hours.
  • water 280 ml
  • conc. hydrochloric acid 450 ml
  • the reaction mixture was cooled to 0° C. and the resulting precipitate was collected by filtration. The obtained crystals were dissolved in hot water and treated with active charcoal and filtered.
  • Step 1 To 2-methyl-6-nitroquinoline-4-carboxamide (231 mg, 1 mmol) obtained in Preparation Example 1-2, Step 1 was added an aqueous sodium hypochlorite solution (0.851 ml,1.2 mmol) and the mixture was stirred at 0° C. for 2.5 hr. The reaction mixture was added dropwise to hot water (10 ml) under reflux with heating and the mixture was refluxed under heating for 20 min. The reaction mixture was cooled to room temperature and the resulting crystals were collected by filtration and dried by heating under reduced pressure to give 4-amino-2-methyl-6-nitroquinoline (177 mg, 87%).
  • N-(4-Hydroxy-2-methyl-6-quinolyl)acetamide (4.32 g, 20 mmol) and phosphorus oxychloride (9.32 ml, 100 mmol) were heated at 100° C. for 15 min.
  • the reaction mixture was cooled to room temperature and poured into ice water. Thereto was added 28% aqueous ammonia to make the solution alkaline.
  • the resulting insoluble matter was collected by filtration, washed with ether and water, dried under reduced pressure at 80° C. to give N-(4-chloro-2-methyl-6-quinolyl)acetamide (6.85 g, crude, yellow solid).
  • N-(2-Methyl-4-methylamino-6-quinolyl)acetamide (248 mg, 1.08 mmol) obtained in Preparation Example 1-3, Step 2 was refluxed under heating for 2 hr in 6N hydrochloric acid (10 ml). The reaction mixture was cooled to room temperature and 4N aqueous sodium hydroxide solution was added to make the pH not lower than 13, followed by ice-cooling. The resulting insoluble matter was collected by filtration and dried under reduced pressure at 60° C. to give the title compound (202 mg, 99.7%, pale-yellow solid).
  • Step 1 To 4-methylsulfonylanisole (505 mg, 2.7 mmol) obtained in Preparation Example 2-3, Step 1 was added 48% aqueous hydrogen bromide (3 ml), and the mixture was refluxed under heating for 10 hr. Water was added to the reaction mixture and the mixture was extracted with chloroform. The organic layer was dried over magnesium sulfate and the solvent was evaporated under reduced pressure to give the title compound (256 mg, 55%, colorless crystals). The obtained compound was used in the next reaction without purification.
  • ORL-1 receptor binding assay was performed, and ⁇ receptor binding assay was performed for the evaluation of selectivity.
  • hot plate test and tail flick test known for long as a test method for analgesic effect were performed, and tactile sensation stimulating test was performed using allodynia model for evaluation of allodynia.
  • a cell membrane suspension obtained from human ORL-1 expression cells was adjusted with Tris buffer [50 mM Tris, 2 mM EDTA, 0.1 mM (p-Amidinophenyl)methanesulfonyl Fluoride Hydrochloride (p-APMSF), 2 mg/ml BSA] to membrane protein amount of about 25 ⁇ g/ml (2.5 ⁇ g/well). This was mixed with [ 3 H]nociceptin (diluted with Tris buffer to a final concentration of 0.5 nM) and test compound (diluted with Tris buffer to a final concentration of 10 nM-10 ⁇ M), and the mixture was incubated at room temperature for 60 min.
  • Tris buffer 50 mM Tris, 2 mM EDTA, 0.1 mM (p-Amidinophenyl)methanesulfonyl Fluoride Hydrochloride (p-APMSF), 2 mg/ml BSA] to membrane protein amount of about 25 ⁇ g/ml (2.5 ⁇
  • the membrane was recovered on a G/F-B filter (Packard, Unifilter 96GF/B) using a cell harvester and the reaction was stopped. After washing 3 times, the filter was dried at 42° C. for 1 hr. A scintillation solution (Packard, microscint-20) was added and the radioactivity (Packard, Top count A9912V) was assayed.
  • a scintillation solution Packard, microscint-20
  • the nonspecific binding was the binding in the presence of 1 ⁇ M nociceptin and the difference between the total binding and nonspecific binding was taken as the specific binding.
  • IC 50 was calculated from inhibition of specific binding at each concentration of the compound, and Ki value of the test compound was calculated from this value and Kd value of [ 3 H]nociceptin.
  • Tris buffer 50 mM Tris-HCl, 0.1 mM p
  • the nonspecific binding was the binding in the presence of 10 ⁇ M naloxone and the difference between the total binding and nonspecific binding was taken as the specific binding.
  • IC 50 was calculated from inhibition of specific binding at each concentration of the compound, and Ki value of the test compound was calculated from this value and Kd value of [ 3 H]DAMGO.
  • mice (Crj, ICR, 4-week-old, male) were placed on a hot-plate (temperature 55.5 ⁇ 0.5° C.) and the time until the mice jumped and tried to run away was recorded. The mice were grouped according to the time and body weight so that the groups were evenly membered. The test compound was suspended in a 0.5% methylcellulose (MC) solution and orally administered to mice. After 60 min, the mice were again placed on a hot-plate and the time until they licked the hindlimb or jumped and tried to run away was recorded. The significant difference from the group administered with solvent was analyzed with ANOVA followed by Dunnett two-tailed test.
  • MC methylcellulose
  • Rats (Crj, SD, 7 or 8-week-old, male) were irradiated with thermal beam at around the base of the tail from below and the time until the rats moved the tail and ran away was measured using a tail-flick analgesic effect measurement device (maufactured by UGO BASILE). Before the administration of the test compound, the measurement was repeated 3 times and the rats were grouped according to the time and body weight so that the groups were evenly membered. The test compound was suspended in a 0.5% MC solution and orally administered to rats. After 30, 60, 90, 120 and 180 minutes from administration, the same measurement was repeated. The significant difference from the group administered with solvent was analyzed with ANOVA followed by Dunnett two-tailed test.
  • mice (Crj, ICR, 4-week-old, male) were intrathecally administered with nociceptin (50 pg/5 ⁇ l) without anesthesia. For 20 min after administration and at 5 min intervals, an area from lateral region to tail of the mice was rubbed with a brush and the response of the mice was observed. The evaluation followed the criteria of 0; no change, 1; run or cry upon tactile stimulation, and 2; cry loud or dash away upon tactile stimulation. The test compound was suspended in a 0.5% MC solution and orally administered 60 min before nociceptin administration. The significant difference of the score of each administration group at 20 min after nociceptin administration from the group administered with solvent was analyzed with Mann-Whitny U-test.
  • the compound of the present invention shows strong analgesic effect due to nociceptin antagonistic action, and a part thereof shows selective action on ORL-1 receptors as compared to opioid receptors ( ⁇ , ⁇ , ⁇ receptors) including ⁇ receptor.
  • the inventive compound can make a pharmaceutical agent effective against pain, particularly strong pain such as postoperative pain and the like or pain caused by sensory nerve abnormality such as hyperalgesia, allodynia and the like.
  • pain particularly strong pain such as postoperative pain and the like or pain caused by sensory nerve abnormality such as hyperalgesia, allodynia and the like.
  • the compound since the compound shows selective action on ORL-1 receptor, it can be a safe pharmaceutical agent without marked side effects.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a compound of the formula [1′]
Figure US20060030565A1-20060209-C00001
wherein R2 is lower alkyl optionally substituted by hydroxy, amino and the like, ring B is phenyl, thienyl and the like, E is a single bond, —O—, —S— and the like, ring G is aryl, heterocyclic group and the like, R5 is halogen atom, hydroxy, lower alkyl optionally substituted by halogen atom etc., and the like, t is 0 or an integer of 1 to 5, when t is an integer of 2 to 5, each R5 may be the same or different, m is 0 or an integer of 1 to 8, and n is 0 or an integer of 1 to 4, and a nociceptin antagonist containing compound [1′] as an active ingredient. The compound [1′] shows, due to nociceptin antagonistic action, analgesic effect against sharp pain such as postoperative pain and the like. The present invention also relates to the use of certain amide derivative inclusive of compound [1′] as a nociceptin antagonist or analgesic.

Description

    TECHNICAL FIELD
  • The present invention relates to a nociceptin antagonist containing a novel amide derivative or a pharmaceutically acceptable salt thereof. More particularly, the present invention relates to an analgesic containing,-as an active ingredient, a novel amide derivative or a pharmaceutically acceptable salt thereof, which show analgesic effect as nociceptin antagonist by selectively acting on an opioid receptor like-1 receptor and which are useful for the treatment of pain, particularly sharp pain or pain caused by sensory nerve abnormality, such as hyperalgesia and allodynia. The present invention moreover relates to a novel use of a certain kind of amide derivative as a nociceptin antagonist and analgesic.
    • BACKGROUND ART
  • Pain is a sensation felt by anybody and is an important vital signal or alarm signal.
  • Pain caused by injury, surgery, inflammation and the like, as well as chronic pain stemming from injury, dysfunction and the like of nerves after recovery from an injury is one of the major clinical problems. Chronic pain sometimes causes autonomic disorder, dyskinesia or mental disorder, wherein the pain itself is the cause of a different disease.
  • There is also known to exist pain due to sensory nerve abnormality, such as hyperalgesia associated with promotion of reaction in response to an ordinary pain stimulus, allodynia wherein pain is felt in response to a stimulus that normally causes no pain, and the like.
  • Analgesics are divided into central analgesic and peripheral analgesic according to the main action site thereof. Inasmuch as the cause of pain is a complicated entanglement of autonomic nerve reactions, feeling and the like, sedative, antianxiety, antidepressant, hypnotic, antispasmodic, vasodilator and the like are used as analgesic auxiliary agents.
  • Central analgesics are roughly divided into narcotic analgesic, anarcotic analgesic and-antipyretic analgesic.
  • Narcotic and anarcotic opioids have been used for the treatment of sharp pain such as postoperative pain and myocardial infarction, burn and the like. These analgesics show noticeable effects resulting from a strong analgesic action combined with an action to remove fear of pain. On the other hand, narcotic analgesics accompany physical dependence and mental dependence and express withdrawal syndrome by drug dependence. Other side effects of respiratory suppresion, nausea, emesis, constipation, dysuria and the like restrict their use.
  • Antipyretic analgesic is effective for superficial pain, such as toothache, myalgia and the like, but is considered to be ineffective for visceralgia. Its antipyretic action is considered to focus on hypothalamus thermoregulation center, and analgesic action is mainly exerted via peripheral nerves. However, there are many unknown parts in the central action mechanism thereof. Its analgesic effect is generally weaker than that offered by narcotic and anarcotic opioids. Consequently, sharp pain is cautiously treated with narcotic and anarcotic opioids in clinical situations to the extent that causes less side effects.
  • Although more than 20 years have passed since the analgesic effect of morphine by intrathecal administration to human was confirmed and morphine was first applied to clinical situations, a pharmaceutical agent exceeding morphine in terms of various side effects, histotoxicity to spinal cord and the like, that accompany analgesic effect of morphine, has not been found.
  • Certain pain caused by injury and functional disorder of nerves and the like is resistant to analgesics currently in clinical use, such as antipyretic analgesic and narcotic analgesic, and shows no significant analgesic effect.
  • Thus, there reaims a demand for a safe and effective analgesic, particularly a strong analgesic free from addiction and an analgesic to treat pain caused by sensory nerve abnormality such as hyperalgesia, allodynia and the like.
  • Pain is caused when an algesic substance, which is released upon occurrence of tissue disorder due to nociceptive stimulus (chemical stimulus, mechanical stimulus, thermal stimulus), excites nociceptor (free nerve terminal) at the sensory nerve terminal, and the information of the pain sensation reaches the cerebral cortex and is recognized as pain. In addition, visceralgia is considered to be caused by the contraction of visceral smooth muscle, that mechanically extends and excites the sensory nerve.
  • Pain sensation is mostly transmitted by two kinds of thin nerve fiber Aδ and C fibers, wherein sharp mechanical stimulus conducts myelinated Aδ fiber and dull pain conducts unmyelinated C fiber. Typical algesic substance includes bradykinin, serotonin, histamine and the like, that act on nociceptor at the nerve terminal. There is a substance that encourages action of an algesic substance, like prostaglandin synthesized at the inflammation site in the peripheral tissue. Such pain afferent fiber (primary afferent fiber) forms synapse on the surface layer of dorsicornu. The primary afferent fiber excites nociceptive neuron via neurotransmitters, such as excitatory amino acid, substance P and the like, and the information is transmitted from dorsicornu to medulla oblongata, thalamus and to cerebral cortex.
  • Pressure and tactile sensation is mainly transmitted by thicker Aβ fiber which transmits the information from sensory nerve terminal to dorsicornu, medulla oblongata, thalamus and to cerebral cortex, like pain afferent fiber.
  • Opioid receptors involved in algesia exist in various parts of these spinothalamic tracts. The respiratory suppressive action, nauseant action and the like result from the action on the opioid receptor in the medulla oblongata. While opioid acts on spinal cord, medulla oblongata, thalamus and cerebral cortex to show strong analgesic effect, suppression of thalamus and cerebral cortex is not its main action. Direct suppression of opioid receptor in the dorsicornu neuron and suppression of dorsicornu neuron by descending depression via midbrain and medulla oblongata are considered to be the main action.
  • Tactile sensation tends to be dull upon sustained application of stimuli of the same intensity. This adaptation is unfeasible in case of pain, but sustained release of neurotransmitter by long-term stimulation of sensory nerve is considered to induce chronic pain by changing the excitatory or information transmission efficiency of the nerve cell. In addition, inhibitory neurotransmitters, such as γ-aminobutyric acid (GABA), glycine and the like, suppress excitement of nerves upon activation of each receptor. While allodynia is considered to be partly induced by dull suppression of neurotransmission due to the stimuli repeatedly applied to the sensory nerve, the mechanism of the onset of chronic pain, hyperalgesia and allodynia has been known only to a limited degree.
  • As described, the sensory nerve transmission is controlled by excitatory nerve fiber and inhibitory nerve fiber in complicated relationship with each other, and many neurotransmitters involved therein have been found to exist. Hence, there are many targets used to find a pharmaceutical agent exhibiting effective analgesic action.
  • Following the discovery of cerebral morphine receptor in 1973, enkephalin, which is an endogenous pentapeptide having analgesic effect, was first found and isolated in 1975. There are known more than 20 kinds of morphinomimetic peptides under the category of opioid peptide, that inhibit the transmission of algesia information.
  • These opioids inclusive of morphine act on opioid receptor. The opioid receptor is known to include several subtypes, wherein morphine shows high affinity for μ receptor, enkephalin shows high affinity for δ receptor and dynorphin shows high affinity for κ receptor, these consisting the base thereof.
  • It is a long-known fact that involvement of μ receptor from among these is important for the analgesic effect and the mechanism thereof has been most elucidated. The study of withdrawal syndrome induction capability and the like of each subtype by the use of opioid antagonist has revealed that the morphine addiction is mainly attributable to the action via μ receptor.
  • An opioid receptor like-1 (ORL-1) receptor has high homology with opioid receptor but does not bind with conventional opioid ligands. This receptor was cloned in 1993.*1*2 In 1995, peptide consisting of 17 amino acids was isolated as endogenous ligand of ORL-1 receptor, and structurally characterized and named Nociceptin or Orphanin FQ *3*4 (*1; FEBS Lett., 341, 33-38, 1994) (*2; FEBS Lett., 347, 284-288, 1994) (*3; Nature, 377, 532-535, 1995) (*4; Science, 270, 792-794, 1995).
  • The amino acid sequence of nociceptin is similar to that of Dynorphin A which is an endogenous opioid peptide. Dynorphin A is a κ receptor agonist showing analgesic effect, but binds weakly with ORL-1 receptor and is said to have no activity*5. Nociceptin binds extremely weakly with an opioid receptor*6, and algesia tests including hot plate test*7 using mouse, scratching of lower abdomen with both hindlimbs of mouse, biting and licking of both hindlimbs (SBL) behavior induction test*8 and the like have revealed its promoting action on transmission of pain information. These reports taught that nociceptin and ORL-1 receptor had specific affinity for each other, and nociceptin was a peptide that induced or amplified pain, conversely from the case of opioid peptide. The study of action mechanism thereof is underway. (*5; Eur. J. Pharmacol., 321, 97, 1997) (*6; J. Biol. Chem., 271, 23642, 1996) (*7; Anesthesia, 45, 1060-1066,1996) (*8; 18th Analgesic, Opioid Peptide Symposium Abstract, 11-14, 1997).
  • ORL-1 receptor has been reported to express more in the central nerve system, such as cerebral cortex, hypothalamus, spinal cord and the like*9, and nociceptin has been shown to be distributed more on the surface layer of dorsicornu where primary pain afferent fiber terminates*10, and algesia transmission of nociceptin is considered to be mainly through central nerve system (*9; J. Neurochemistry, 64, 34-40, 1995) (*10; Neuro Report 7, 3021-3025, 1996).
  • It has been also reported that administration of nociceptin induces nociceptive hypersensitivity (hyperalgesia*3*4, allodynia*11) and that it amplifies excitatory stimulus by heat and tactile (*11; Molecular Brain Research, 43, 96-104, 1996).
  • Under the circumstances, substances reported to exhibit a nociceptin antagonistic action are only nociceptin-like polypeptide and naloxone benzoylhydrazone which is a κ receptor antagonist having a morphine-like structure, both of which having ORL-1 receptor affinity, and a pharmaceutical agent having specific antagonistic action on ORL-1 receptor has not been developed.
  • Known analgesic having a quinoline skeleton includes opioid or anesthetic antagonist analgesic [Japanese Patent Unexamined Publication No. 63-264460 (EP 277794; BOC Inc.)], analgesic having a different action mechanism [Japanese Patent Unexamined Publication No. 62-503030 (U.S. Pat. No. 5,104,884; Alkaloida Vegyeszeti Gyar, antifungal action), WO96/13485 (EP 807105; Fujisawa Pharmaceutical Industries, Ltd., bradykinin antagonist), WO96/11930 (Smithkline beecham P.L.C., serotonin receptor antagonist), Japanese Patent Unexamined Publication No. 59-210084 (U.S. Pat. No. 4,839,366; Chiesi Farmaceutici S.p.A., prostaglandin synthesis inhibition), Japanese Patent Unexamined Publication No. 54-73784 (U.S. Pat. No. 4,293,549; Leo Pharmaceutical Products Limited A/S), FR 1557928 and FR 1543405 (M. Robert ARIES) and the like. These do not include a compound having the structure of the inventive compound, nor do they disclose an action on nociceptin or ORL-1 receptor as in the present invention.
  • Compounds having a quinoline skeleton structurally similar to that in the inventive compound and which can be used for effects other than analgesic effect are shown in DE 831100 and DE 947552 (anti-blood parasite agent), WO97/14681 (therapeutic agent of bone metabolism abnormality), Japanese Patent Unexamined Publication No. 63-99069 (U.S. Pat. No. 4,753,951; antipsychotic agent), Japanese Patent Unexamined Publication No. 2-167265 (U.S. Pat. No. 5,019,574; psychoneurotic function improving agent), Journal of American Chemistry Society (76, 3703-3708, 1956) (antibacterial agent), HU34479 {disclosure of quinoline skeleton as a synthetic intermediate for imidazo[4,5-c]quinoline derivative (analgesic)) and the like, though none of which discloses effectiveness as an analgesic.
    • DISCLOSURE OF THE INVENTION
  • Based on the foregoing findings, a pharmaceutical agent having nociceptin antagonistic action can make an effective agent for pain, particularly sharp pain such as postsurgery pain and the like or pain caused by sensory nerve abnormality, such as hyperalgesia, allodynia and the like, and a safe pharmaceutical agent showing selective action on ORL-1 receptor and free of marked side effects.
  • It is therefore an object of the present invention to provide a pharmaceutical agent having an action mechanism different from that of known analgesics, via nociceptin antagonistic action.
  • It is also an object of the present invention to provide a novel compound having a nociceptin antagonistic action, which is useful as an analgesic.
  • As a result of the intensive study of the present inventors in an attemp to solve the above-mentioned problems, the present invention now provides a hovel compound having an analgesic effect.
  • The present invention specifically provides the following (1) to (20).
  • (1) A nociceptin antagonist containing an amide derivative of the formula [1]
    Figure US20060030565A1-20060209-C00002
    wherein
  • R1 and R2 are the same or different and each is hydrogen atom, lower alkyl optionally substituted by hydroxy, amino, lower alkylamino or di(lower)alkylamino;
  • R3 and R4 are the same or different and each is hydrogen atom, halogen atom or lower alkyl;
  • ring A is aryl or heterocyclic group;
  • ring B is phenyl, thienyl, furyl, pyrrolyl, pyrrolidinyl, oxazolyl or cyclohexenyl; and
  • X is hydrogen atom, halogen atom, lower alkyl optionally substituted by lower alkoxy, lower alkenyl, amino, cyano or a group of the formula
    Figure US20060030565A1-20060209-C00003
  • wherein E is a single bond, carbonyl, sulfinyl, —O—, —S—, —NHCO—, —CH═CR6— wherein R6 is hydrogen atom or aryl or —NR7— wherein R7 is hydrogen atom, lower alkyl or lower alkoxycarbonyl;
  • ring G is aryl, heterocyclic group, cycloalkyl or condensed aryl;
  • R5 is halogen atom, hydroxy, lower alkyl Optionally substituted by any of halogen atom, hydroxy, lower alkanoyloxy and lower alkoxy optionally substituted by lower alkoxy, lower alkoxy optionally substituted by lower alkoxy, amino, lower alkylamino, di(lower)alkylamino, nitro, cyano, lower alkanoyl, lower alkanoyloxy,
  • carboxy, lower alkoxycarbonyl, lower alkylsulfonyl or phenyl;
  • t is 0 or an integer of 1 to 5, which indicates
  • the number of substituents on the ring G, wherein when t is an integer of 2 to 5, each R5
  • may be the same or different;
  • m is 0 or an integer of 1 to 8; and
  • n is 0 or an integer of 1 to 4, or a pharmaceutically acceptable salt thereof as an active ingredient.
  • (2) A nociceptin antagonist containing the amide derivative of (1) above wherein the ring A is quinolyl or a pharmaceutically acceptable salt thereof as an active ingredient.
  • (3) A nociceptin antagonist containing the amide derivative of (1) above wherein the ring B is phenyl and X is a group of the formula
    Figure US20060030565A1-20060209-C00004
  • wherein E, ring G, R5, t, m and n are as defined in (1), or a pharmaceutically acceptable salt thereof as an active ingredient.
  • (4) A nociceptin antagonist containing the amide derivative of (3) above wherein the ring A is
    Figure US20060030565A1-20060209-C00005
  • wherein R8 is lower alkylthio, or a pharmaceutically acceptable salt thereof as an active ingredient. (5) An amide derivative of the formula [1′]
    Figure US20060030565A1-20060209-C00006
  • wherein R2, ring B, E, ring G, R5, t, m and n as defined in (1), or a pharmaceutically acceptable salt thereof.
  • (6) The amide derivative of (5) above, wherein the ring B is phenyl and R2 is lower alkyl, or a pharmaceutically acceptable salt thereof.
  • (7) The amide derivative of (6) above, wherein the amino substitutes at the 4-position on a quinoline skeleton, R2 is methyl substituting at the 2-position on the quinoline skeleton, E is —O— and the ring B of phenyl has a substituent of the formula
    Figure US20060030565A1-20060209-C00007
  • wherein ring G, R5, t, m and n as defined in (1), at the 2-position, or a pharmaceutically acceptable salt thereof.
  • (8) The amide derivative of (7) above or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-ethylphenoxy)-methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(2,4-dichlorophenoxy)-methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-(phenoxymethyl)benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-methoxyphenoxy)methyl]-benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(3,5-dimethylphenoxy)-methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(3,4-dimethoxyphenoxy)-methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-((4-nitrophenoxy)-methyl]benzamide,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(2,3-dimethoxyphenoxy)-methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(3-methylphenoxy)-methyl]benzamide,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(3,5-dimethoxyphenoxy)-methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-chlorophenoxy)-methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-acetylphenoxy)-methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-hydroxyphenoxy)-methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-methoxymethoxyphenoxy)-methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(3-methoxyphenoxy)-methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-cyanophenoxy)methyl]-benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-methylphenoxy)-methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-trifluoromethylphenoxy)methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(3-nitrophenoxy)methyl]-benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(2-nitrophenoxy)methyl]-benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-acetoxyphenoxy)methyl]-benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(2-methoxyphenoxy)methyl]-benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-((4-aminophenoxy)methyl]-benzamide dihydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(3-chlorophenoxy)methyl]-benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-fluorophenoxy)methyl]-benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(3,4-dichlorophenoxy)-methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(2-chlorophenoxy)methyl]-benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-dimethylaminophenoxy)-methyl]benzamide dihydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-tert-butylphenoxy)-methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-(4-biphenylyloxymethyl)-benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-isopropylphenoxy)-methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-nitrophenoxy)methyl]-benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-bromophenoxy)methyl]-benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-propylphenoxy)methyl]-benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(3-fluorophenoxy)methyl]-benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[((3-trifluoromethylphenoxy)methyl]benzamide hydrochloride,
    • methyl 4-[2-{N-(4-amino-2-methyl-6-quinolyl)carbamoyl}-benzyloxy]benzoate hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-iodophenoxy)methyl]-benzamide,
    • N-(4-amino-2-methyl-6-quinolyl)-2-(3-pyridyloxymethyl)-benzamide hydrochloride,
    • 4-[2-{(4-amino-2-methyl-6-quinolyl)carbamoyl}benzyloxy]-benzoate hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(3-cyanophenoxy)methyl]-benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-mesylphenoxy)methyl]-benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(2-chloro-4-ethylphenoxy)-methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-((4-chloro-3-methylphenoxy)methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(2-chloro-4-methylphenoxy)methyl]benzamide hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-ethylphenoxy)-methyl]benzamide,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-chloro-3-methylphenoxy)methyl]benzamide,
    • 4-[2-{(4-amino-2-methyl-6-quinolyl)carbamoyl}benzyloxy]benzyl acetate hydrochloride,
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-hydroxymethylphenoxy)-methyl]benzamide hydrochloride and
    • N-(4-amino-2-methyl-6-quinolyl)-2-[(4-ethylphenoxy)methyl]-benzamide hydrochloride monohydrate.
  • (9) An amide derivative of the formula [1″]
    Figure US20060030565A1-20060209-C00008
    wherein the ring A, R2, R5 and t are as defined in (1), or a pharmaceutically acceptable salt thereof.
  • (10) A pharmaceutical composition comprising the amide derivative of any of (5) to (9) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • (11) A nociceptin antagonist containing the amide derivative of any of (5) to (9) or a pharmaceutically acceptable salt thereof as an active ingredient.
  • (12) An analgesic containing the amide derivative of any of (1) to (9) or a pharmaceutically acceptable salt thereof as an active ingredient.
  • (13) A method for expressing a nociceptin antagonistic action, comprising administering the amide derivative of any of (1) to (9) or a pharmaceutically acceptable salt thereof.
  • (14) A method for treating pain, comprising administering the amide derivative of any of (1) to (9) or a pharmaceutically acceptable salt thereof.
  • (15) Use of the amide derivative of any of (1) to (9) or a pharmaceutically acceptable salt thereof for the production of a nociceptin antagonist.
  • (16) Use of the amide derivative of any of (1) to (9) or a pharmaceutically acceptable salt thereof for the production of an analgesic.
  • (17) A pharmaceutical composition for antagonizing nociceptin, which comprises the amide derivative of any of (1) to (9) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • (18) A commercial package comprising the pharmaceutical composition of (17) and a written matter associated therewith, the written matter stating that the pharmaceutical composition can be or should be used for antagonizing nociceptin.
  • (19) A pharmaceutical composition for analgesic use, which comprises the amide derivative of any of (1) to (9) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
  • (20) A commercial package comprising the pharmaceutical composition of (19) and a written matter associated therewith, the written matter stating that the pharmaceutical composition can be or should be used for analgesia.
  • Each substituent and moiety used in the present specification are defined as follows.
  • Halogen atom is fluorine atom, chlorine atom, bromine atom or iodine atom. At R3, R4, R5 and R5″, it is preferably chlorine atom.
  • Lower alkyl has linear or branched chain and 1 to 6 carbon atoms. Specific examples thereof include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, tert-pentyl, hexyl and the like.
  • It is preferably a linear or branched alkyl having 1 to 4 carbon atoms. At R3, R4, R7, R9, R10, R11 and R2′, it is more preferably methyl and at R5′, it is more preferably methyl or ethyl.
  • Lower alkoxy has an alkyl moiety defined above as lower alkyl. Specific examples include methoxy, ethoxy, propoxy, isopropyloxy, tert-butoxy and the like.
  • Lower alkylthio has an alkyl moiety defined above as lower alkyl. Specific examples include methylthio, ethylthio, propylthio, isopropylthio, tert-butylthio and the like.
  • Preferably, its alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms. At R8, it is more preferably methylthio.
  • Lower alkanoyl has an alkyl moiety defined above as lower alkyl. Specific examples include acetyl, propionyl, butyryl, isobutyryl, pivaloyl and the like.
  • Preferably, its alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms. At R5, it is more preferably acetyl.
  • Lower alkylsulfonyl has an alkyl moiety defined above as lower alkyl. Specific examples include mesyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, tert-butylsulfonyl and the like.
  • Preferably, its alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms. At R5, it is more preferably mesyl.
  • Lower alkanoyloxy has an alkyl moiety defined above as lower alkyl. Specific examples include acetoxy, propionyloxy, butyryloxy, isobutyryloxy, pivaloyloxy and the like.
  • Preferably, its alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms. At R5, it is more preferably acetoxy.
  • Lower alkoxycarbonyl has an alkyl moiety defined above as lower alkyl. Specific examples include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropyloxycarbonyl, tert-butoxycarbonyl and the like.
  • Preferably, its alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms. At R5, it is more preferably methoxycarbonyl, and at R7, it is more preferably tert-butoxycarbonyl.
  • Lower alkyl optionally substituted by hydroxy means that the above-defined lower alkyl is optionally substituted by one or more hydroxy, and that the lower alkyl may be unsubstituted. Specific examples include methyl, ethyl, propyl, isopropyl, hydroxymethyl, 1,2-dihydroxyethyl, 2-(hydroxymethyl)butyl and the like.
  • R1 and R2 are preferably methyl, ethyl, propyl, isopropyl or hydroxymethyl, and more preferably methyl or ethyl.
  • Lower alkyl optionally substituted by lower alkoxy means the above-defined lower alkyl optionally substituted by the above-defined lower alkoxy, including unsubstituted alkyl. Specific examples include methyl, ethyl, methoxymethyl, ethoxymethyl, 2-(methoxymethyl)butyl and the like.
  • Preferably, its base alkyl moiety is a linear alkyl having 1 to 4 carbon atoms. At X, it is more preferably methoxymethyl.
  • Lower alkoxy optionally substituted by lower alkoxy means the above-defined lower alkoxy optionally substituted by the above-defined lower alkoxy, including unsubstituted alkoxy. Specific examples include methoxy, ethoxy, methoxymethoxy, methoxyethoxy, 2-(methoxymethyl)butyloxy and the like.
  • Preferably, its base alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms. At R5, it is more preferably methoxy or methoxymethoxy.
  • Lower alkyl optionally substituted by any of halogen atom, hydroxy, lower alkanoyloxy and lower alkoxy optionally substituted by lower alkoxy means that the above-defined lower alkyl is optionally substituted by one or more of the above-defined halogen atom, hydroxy, the above-defined lower alkanoyloxy and the above-defined lower alkoxy optionally substituted by lower alkoxy, each of which may be the same or different, and that the lower alkyl may be unsubstituted. Specific examples include methyl, ethyl, propyl, isopropyl, tert-butyl, hydroxymethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, acetoxymethyl, pivaloyloxymethyl, bromomethyl, trifluoromethyl, methoxymethoxymethyl, methoxyethoxymethyl and the like.
  • Preferably, its base alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms. At R5, it is more preferably methyl, ethyl, propyl, isopropyl, tert-butyl, hydroxymethyl, acetoxymethyl, trifluoromethyl or methoxymethoxymethyl and more preferably ethyl.
  • Lower alkylamino is a monoalkylamino group wherein the alkyl moiety is defined above as lower alkyl. Specific examples include methylamino, ethylamino, propylamino, isopropylamino, tert-butylamino and the like.
  • Preferably, its alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms. At R1 and R2, it is more preferably methylamino.
  • Di(lower)alkylamino is a dialkylamino group wherein the alkyl moiety is the same or different and as defined above as lower alkyl. Specific examples include dimethylamino, diethylamino, methylethylamino, N-isopropyl N-isobutylamino and the like.
  • Preferably, its alkyl moiety is a linear or branched alkyl having 1 to 4 carbon atoms. At R1, R2 and R5, it is more preferably dimethylamino.
  • Lower alkenyl is linear chain alkenyl having 1 to 6 carbon atoms. Examples thereof include vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,3-butadienyl, 2,4-butadienyl, 1-pentenyl, 1,3-pentadienyl and 1,3,5-hexatrienyl and the like.
  • X is preferably vinyl.
  • Aryl is an aromatic hydrocarbon group having 6 to 18 carbon atoms. Examples thereof include phenyl, naphthyl, anthryl, indenyl, azulenyl, fluorenyl, phenanthryl, pyrenyl and the like.
  • Ring A is preferably phenyl and naphthyl, more preferably phenyl. Ring G and R6 are preferably phenyl.
  • When ring G is phenyl, substituent R5 is preferably bonded at para-position.
  • Heterocyclic ring is a cyclic compound group having one or more from oxygen atom, nitrogen atom and sulfur atom as hetero atom, wherein plural hetero atoms may be contained and the number of atoms constituting the ring is 5 to 20. Specific examples thereof include pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, thienyl, furyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, quinolyl, isoquinolyl, indolyl, benzofuranyl, benzimidazolyl, imidazolidinyl, indolinyl, pyrrolidinyl, pyrolinyl, piperidinyl, piperazinyl, chromanyl, morpholinyl, phthalazinyl, naphthyridinyl, quinazolinyl, quinoxalyl, cinnolinyl, pteridinyl, 4H-quinolizinyl, carbazolyl, 1,3,5-triazinyl, 2,3-dihydrobenzofuranyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroacridinyl, 2,3-dihydro-1H-cyclopenta[b]quinolyl and the like.
  • Ring G is preferably pyridyl, benzofuranyl or 2,3-dihydrobenzofuranyl, more preferably 2,3-dihydrobenzofuranyl.
  • Ring A is preferably a cyclic compound group containing one or more nitrogen atoms as hetero atoms, and the number of atoms constituting the ring is 9 to 14. More preferably, it is quinolyl, isoquinolyl, quinoxalyl, benzimidazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroacridinyl or 2,3-dihydro-1H-cyclopenta[b]quinolyl, most preferably quinolyl, 5,6,7,8-tetrahydroacridinyl or 2,3-dihydro-1H-cyclopenta[b]quinolyl.
  • When the ring A is quinolyl, it is preferable that R1 be an amino group substituting at the 4-position, R2 be a lower alkyl substituting at the 2-position and —NHCO— substitute at the 6-position.
  • Cycloalkyl is a saturated cycloalkyl having 3 to 8 carbon atoms, which is exemplified by cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cycloctyl.
  • Ring G is preferably cyclohexyl.
  • Condensed aryl is the above-defined aryl wherein the above-defined cycloalkyl groups are condensed, which is a cyclic compound-group wherein the number of atoms constituting the ring is 5 to 18. Specific examples include indanyl, 5,6,7,8-tetrahydro-2-naphthyl, 5,6,7,8-tetrahydro-3-naphthyl, 12,3,4-tetrahydro-2-naphthyl, 5.6,7,8-tetrahydro-2-anthryl, 1,2,3-trihydroazulenyl and the like.
  • Ring G is preferably 5,6,7,8-tetrahydro-2-naphthyl.
  • Protected amino is an amino group protected by an amino-protecting group used in a typical chemical synthesis. Specific examples of the amino-protecting group include formyl, acetyl, benzoyl, benzyloxycarbonyl, methoxycarbonyl, tert-butoxycarbonyl, phthaloyl, benzyl, tosyl and the like.
  • Carboxy-protecting group is a carboxy-protecting group used in a typical chemical synthesis. Specific examples thereof include methyl, methoxyethoxymethyl, phenacyl, phthalimidomethyl, ethyl, 2,2,2-trichloroethyl, 2-methylthioethyl, tert-butyl, benzyl, p-nitrobenzyl, p-methoxybenzyl, tert-butyldimethylsilyl and the like.
  • Hydroxy-protecting group is a hydroxy-protecting group used in a typical chemical synthesis. Specific examples thereof include trimethylsilyl, tert-butyldimethylsilyl, methyl, benzyl, p-methoxybenzyl, tert-butyl, trityl, tetrahydropyranyl, methoxymethyl, methoxyethoxyethyl, acetyl, benzoyl and the like.
  • In the above-mentioned formulas [1], [1′] and [1″], each symbol preferably means the following.
  • Ring G is preferably aryl.
  • R5 is preferably halogen atom; lower alkyl optionally substituted by any of halogen atom, hydroxy, lower alkanoyloxy and lower alkoxy optionally substituted by lower alkoxy; lower alkoxy optionally substituted by lower alkoxy; nitro; cyano; or lower alkanoyl, and more preferably lower alkyl optionally substituted by any of halogen atom, hydroxy, lower alkanoyloxy and lower alkoxy optionally substituted by lower alkoxy.
  • The t is preferably O or an integer of 1 or 2, more preferably 1.
  • The E is preferably a single bond or —O—, more preferably —O—.
  • When E is —O—, m is preferably an integer of 1 to 7, lo more preferably 1, and n is preferably 0. When E is a single bond, m+n is preferably 2.
  • The compound of the formula [1] includes various isomers. For example, there exist geometric E- and Z-isomers. When asymmetrical carbon atom(s) exist(s), stereoisomers (e.g., enantiomer and diastereomer) exist. Depending on the case, tautomers may exist in the present invention. Therefore, the present invention encompasses all these isomers and mixtures thereof.
  • The pharmaceutically acceptable salt thereof may be any salt as long as it can form a nontoxic salt with the compound of the above-mentioned formula (1], [1′] or [1″]. Examples thereof include salts with inorganic acid such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like; salts with organic acid such as oxalic acid, malonic acid, citric acid, fumaric acid, lactic-acid, malic acid, succinic acid, tartaric acid, acetic acid, gluconic acid, ascorbic acid, methylsulfonic acid, benzylsulfonic acid and the like; salts with inorganic base such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, ammonium hydroxide and the like; salts with organic base such as methylamine, diethylamine, triethylamine, triethanolamine, ethylenediamine, tris(hydroxymethyl)methylamine, guanidine, choline, cinchonine and the like; or salts with amino acid such as lysine, arginine, alanine and the like. The present invention further encompasses water-containing compounds and hydrates and solvates of each compound.
  • The present invention further encompasses prodrugs and metabolites of each compound. Prodrug is a derivative of the compound of the present invention, which has a chemically or metabolically decomposable group and which shows efficacy upon restoration to its original form after administration to a body, wherein included therein are a complex without a covalent bond and salts.
  • When the compound of the present invention is used as a pharmaceutical preparation, it is generally admixed with conventionally known pharmaceutically acceptable carrier, excipient, diluent, extender, disintegrator, stabilizer, preservative, buffer, emulsifier, aromatic, coloring agent, sweetener, tackifier, flavor, solubilizer and other additive, specifically water, vegetable oil, alcohol (e.g., ethanol, benzyl alcohol and the like), polyethylene glycol, glycerol triacetate, gelatin, carbohydrate (e.g., lactose, starch and the like), magnesium stearate, talc, lanolin, petrolatum and the like, and formulated into tablets, pills, powders, granules, suppositories, injections, eye drops, liquids, capsules, troches, aerosols, elixirs, suspensions, emulsions, syrups and the like by a conventional method, which can be administered systemically or locally by oral or parenteral administration.
  • While the dose varies depending on age, body weight, symptom, therapeutic effect, administration route and the like, it is generally 0.01 mg to 1 g per dose which is given once to several times a day for an adult.
  • One example of the production method of the compound to practice the present invention is explained in the following, to which the production method of the compound of the present invention is not limited.
  • In each step, the treatment of reaction may be a conventional one, such as isolation and purification, crystallization, recrystallization, silica gel column chromatography, preparative HPLC and the like, which may be appropriately selected and combined. Where necessary, a protecting group may be introduced into a functional group and deprotected for production.
  • Production Method 1
  • A synthetic method of the compound of the following formula [I] is shown in the following.,
    Figure US20060030565A1-20060209-C00009
    wherein ring A, R1, R2 and R3 are as defined above.
  • When ring A is a quinoline ring, the quinoline synthetic method of Camps, the quinoline synthetic method of Combes, the quinoline synthetic method of Friedlander, the quinoline synthetic method of Knorr, the quinoline synthetic method of Niementowski and the like can be used for synthesis. A part of the compound can be obtained as a commercially available reagent.
  • The Production methods of quinoline ring having substituent are show in the following.
  • Production Method 1-1
  • In this production method, β-keto acid ester and aniline compound are reacted to give 4-hydroxyquinoline compound.
    Figure US20060030565A1-20060209-C00010
    wherein R3 is as defined above, R2′ is lower alkyl and Y is nitro or protected amino.
    Step 1
  • Compound [I-1] and compound [I-2] are condensed in an alcohol solvent, such as methanol, ethanol, n-propanol, isopropanol and the like, at room temperature or under heating to give compound [I-3].
  • Step 2
  • Compound [I-3] obtained in Production method 1-1, Step 1 is added by portions to a heated solvent and cyclized to give compound [I-4].
  • Preferable solvent is diphenyl ether or a mixture of diphenyl ether and diphenyl such as Dowtherm A (trademark Fluka).
  • This production method can be applied to compound [I-1] wherein the α-position of β-keto acid ester is substituted by lower alkyl.
  • Production Method 1-2
  • According to this production method, quinoline compound is obtained from isatin compound.
    Figure US20060030565A1-20060209-C00011
    wherein R3 and Y are as defined above.
    Step 1
  • Compound [I-5], acetone and aqueous ammonia are reacted under pressurization and under heating to give compound [I-6].
  • Step 2
  • Compound [I-6] obtained in Production method 1-2, Step 1 is reacted in the presence of oxidizing agent, such as sodium hypochlorite, sodium hypobromite and the like, under cooling, and the obtained reaction mixture is added dropwise into hot water and further heated to give compound [I-7].
  • The following production method can be used to introduce a specific substituent or into a specific substitution site.
  • Production Method 1-3
  • According to this production method, 4-hydroxy-2-methoxycarbonylquinoline compound is obtained from acetylenedicarboxylate compound and aniline compound. The methoxycarbonyl group of this compound can be converted to hydroxymethyl group by reduction in a later step.
    Figure US20060030565A1-20060209-C00012
    wherein R3 and Y are as defined above.
    Step 1
  • Compound [I-8] and compound [I-9] are condensed in the same manner as in Production method 1-1, Step 1 to give compound [I-10].
  • Step 2
  • Compound [I-10] obtained in Production method 1-3, Step 1 is cyclized in the same manner as in Production method 1-1, Step 2 to give compound [I-11].
  • Production Method 1-4
  • According to this production method, 4,6-diaminoquinoline compound is obtained from 4-nitroquinoline N-oxide compound.
    Figure US20060030565A1-20060209-C00013
    Step 1
  • Compound [I-12] and metal iron are reacted in an acid solvent, such as hydrochloric acid, acetic acid and the like, under heating and the resulting solution is made alkaline to give compound [I-13].
  • Alternatively, a typical reduction using tin or tin (II) chloride and conc. hydrochloric acid; alkaline metal sulfide such as aqueous sodium sulfide solution; catalytic reduction and the like may be used.
  • Step 2
  • Compound [I-13] obtained in Production method 1-4, Step 1 is treated with bromine in acetic acid under cooling or at room temperature to halogenate to give compound [1-14].
  • Alternatively, halogenating agent such as hypohalite (e.g., hypochlorite and the like), N-bromosuccinimide and the like can be used instead of bromine for halogenation.
  • Step 3
  • Compound [I-14] obtained in Production method 1-4, Step 2 is subjected to nitration in a sulfuric acid solvent under cooling by adding conc. nitric acid to give compound [I-15].
  • Nitric acid or inorganic nitrate-sulfuric acid may be used instead of a mixture of nitric acid-sulfuric acid for nitration.
  • Step 4
  • Compound [I-15] obtained in Production method 1-4, Step 3 is subjected to catalytic reduction using a hydrogenating catalyst in an alcohol solvent such as methanol, ethanol, n-propanol, isopropanol and the like by adding hydrochloric acid or hydrogen bromide-acetic acid solution at room temperature or under heating under normal pressure to high pressure to give compound [I-16].
  • Examples of hydrogenating catalyst include palladium carbon, palladium hydroxide, palladium black, Raney-nickel, platinum oxide and the like.
  • Examples of synthesis when ring A is isoquinoline ring are shown in the following.
  • Production Method 1-5
  • According to this production method, 1-halogeno-7-nitroisoquinoline is obtained from tetrahydroisoquinoline.
    Figure US20060030565A1-20060209-C00014
    Step 1
  • Compound [I-17] is subjected to nitration in the same manner as in Production method 1-4, Step 3 to give compound [I-18].
  • Step 2
  • Compound [I-18] obtained in Production method 1-5, Step 1 is subjected to dehydrogenation for a few days using Fremy's salt in 4% aqueous sodium carbonate solution at room temperature to give compound [I-19].
  • Step 3
  • Compound [I-19] obtained in Production method 1-5, Step 2 is reacted with m-chloroperbenzoic acid in a halogen solvent, such as dichloromethane, chloroform, carbon tetrachloride and the like, at room temperature for N-oxidation to give compound [I-20].
  • Step 4
  • Compound [I-20] obtained in Production method 1-5, Step 3 is reacted with phosphorus oxychloride in a hydrocarbon solvent, such as toluene, xylene and the like, under heating to give compound [I-21].
  • Production Method 1-6
  • According to this production method, quinoline compound condensed with cycloalkyl is obtained by condensation of saturated cyclic ketone and anthranilonitrile compound.
    Figure US20060030565A1-20060209-C00015
    wherein Y is as defined above and p is 0 or an integer of 1.
  • An acid catalyst such as Lewis acid (e.g., zinc chloride) is added to a mixture of Compound [I-22] and compound [I-23] under heating for condensation to give compound [I-24].
  • Production Method 1-7
  • According to this production method, a substituent of a compound is substituted by amino group or substituted amino group.
    Figure US20060030565A1-20060209-C00016
    wherein ring A, R2, R3 and Y are as defined above, R9 is hydrogen-atom or lower alkyl and R10 is lower alkyl.
    Step 1
  • Compound [I-25] obtained in Production method 1-1 or a commercially available reagent is reacted with chlorosulfonyl isocyanate in acetonitrile or dichloroethane under heating to give compound [I-26].
  • Step 2
  • Compound [I-25] obtained in Production method 1-1 or a commercially available reagent is reacted with an alkylating agent in a solvent under heating or at room temperature to give compound [I-27].
  • As the alkylating agent, dimethyl sulfate or methyl p-toluenesulfonate is used to introduce methoxy group in the scheme.
  • Examples of preferable solvent include hydrocarbon solvent such as benzene, toluene, hexane, xylene and the like; and ether solvent such as 1,4-dioxane, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran and the like.
  • Step 3
  • Compound [I-25] obtained in Production method 1-1 or a commercially available reagent is reacted with halogenating agent, such as phosphorus oxychloride, phosphorus pentachloride and the like, under heating and the reaction mixture is made alkaline to give compound [I-28].
  • Step 4
  • Compound [I-28] obtained in Production method 1-5 or Production method 1-7, Step 3 or commercially available reagent is reacted with metal alkoxide in an alcohol solvent, such as methanol, ethanol, propanol, butanol and the like, under heating to give compound [I-27].
  • As the metal alkoxide, sodium methoxide is used and as the solvent, methanol is used as the corresponding alcohol solvent to introduce methoxy shown in the scheme.
  • Step 5
  • Compound [I-27] obtained in Production method 1-7, Step 2 or Production method 1-7, Step 4 or commercially available reagent is reacted with aminating agent such as ammonium acetate and the like under heating to give compound [I-26].
  • Step 6
  • Compound [I-28] obtained in Production method 1-7, Step 3 or commercially available reagent is reacted with compound [I-29] in the presence of a base, such as potassium carbonate, sodium carbonate, sodium hydroxide, potassium hydroxide, lithium hydroxide and the like, under heating to give compound [I-30].
  • The compound [I-25] in this Production method 1-7 may be compound [I-11] obtained in Production method 1-3.
  • Production Method 1-8
  • According to this production method, amino-protecting group of a compound is eliminated or nitro group of a compound is reduced.
    Figure US20060030565A1-20060209-C00017
    wherein ring A, R1, R2, R3 and Y are as defined above.
  • When Y is a protected amino, a typical deprotection method corresponding to the protecting group is used.
  • For example, when the protecting group is acetyl, conc. hydrochloric acid is added to compound [I-31] obtained in Production method 1-7 or a commercially available reagent, and the mixture is heated for deacetylation to give compound [I].
  • Instead of conc. hydrochloric acid treatment, heating in conc. ammonia, potassium hydroxide treatment and the like may be used.
  • When Y is nitro, a typical method of conversion to amine by reduction of nitro is used. For example, compound [I-31] obtained in Production method 1-7 or commercially available reagent is subjected to catalytic reduction in a solvent at room temperature or under heating, at normal pressure or high pressure using a hydrogenating catalyst to give compound [I].
  • Examples of the solvent include ether solvent such as 1,4-dioxane, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran and the like; polar solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone and the like; alcohol solvent such as methanol, ethanol, propanol, butanol and the like; ester such as ethyl formate, ethyl acetate, butyl acetate and the like; water; or a mixed solvent thereof.
  • The hydrogenating catalyst is exemplified by palladium carbon, palladium hydroxide, palladium black, Raney-nickel, platinum oxide and the like.
  • Production Method 2
  • The synthetic method of the compound of the formula [II] is shown in the following.
    Figure US20060030565A1-20060209-C00018
    wherein ring B, R4 and X are as defined above.
  • When X is a group of the formula
    Figure US20060030565A1-20060209-C00019
    wherein ring G, R5 and t are as defined above, the following Production method is exemplified.
    Production Method 2-1
  • According to this production method, methyl of a methyl-substituted carboxylic acid compound is converted to ether.
    Figure US20060030565A1-20060209-C00020
    wherein ring B, ring G, R4, R5 and t are as defined above, and Z is a carboxy-protecting group.
    Step 1
  • Compound [II-1] is reacted with radical initiator such as benzoyl peroxide, azobisisobutyronitrile and the like and N-bromosuccinimide to give compound [II-2].
  • Step 2
  • Compound [II-2] obtained in Production method 2-1, Step 1 is reacted with compound [II-3] in a solvent in the presence of a base, such as potassium carbonate, sodium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium hydride, sodium hydride, potassium hydride and the like, under heating to give compound [II-4].
  • Examples of the solvent include hydrocarbon solvent such as benzene, toluene, hexane, xylene and the like; ether solvent such as 1,4-dioxane, diethylether, 1,2-dimethoxyethane, tetrahydrofuran and the like; polar solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone and the like; and alcohol solvent such as methanol, ethanol, propanol, butanol and the like.
  • Most of compound [II-3] can be easily obtained as a commercially available reagent but a compound difficult to obtain can be synthesized by the following production methods.
  • Production Method 2-2
  • According to this production method, a cyclic compound having a substituent is substituted by halogen atom.
    Figure US20060030565A1-20060209-C00021
    wherein ring G is as defined above, R5′ is lower alkyl and R5‘ is halogen atom.
  • In the same manner as in Production method 1-4, Step 2, compound [II-5] is halogenated to give compound [II-6].
  • Using sulfuryl chloride as the halogenating agent, the compound is halogenated in a halogen solvent, such as dichloromethane, chloroform, carbon tetrachloride, tetrachloroethylene and the like, to substitute chlorine atom at the ortho-position of 4-alkyl substituted phenol.
  • Production Method 2-3
  • According to this production method, a cyclic compound is substituted by alkylsulfonyl.
    Figure US20060030565A1-20060209-C00022
    wherein ring G is as defined above, Q is a hydroxy-protecting group and R11 is lower alkyl.
    Step 1
  • Compound [II-7] is reacted with alkylsulfonic anhydride, such as methanesulfonic anhydride, in a halogen solvent, such as dichloromethane, chloroform, carbon tetrachloride, tetrachloroethylene and the like, under heating to give compound [II-8].
  • Step 2
  • Compound [II-8] obtained in Production method 2-3, Step 1 is deprotected by a conventional method to give compound [II-9].
  • For example, when R11 is methyl, aqueous hydrogen bromide is added and heated, or heated with sodium cyanide in dimethyl sulfoxide to allow deprotection.
  • Production Method 2-4
  • According to this production method, benzofuran compound or 2,3-dihydrobenzofuran compound is synthesized from phenol compound.
    Figure US20060030565A1-20060209-C00023
    wherein Q is as defined above.
    Step 1
  • Compound [II-10] is condensed with compound [II-11] in a polar solvent, such as dimethylformamide, dimethyl sulfoxide, acetonitrile, acetone and the like, in the presence of a base, such as potassium carbonate, sodium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium hydride, sodium hydride, potassium hydride and the like, under heating to give compound [II-12].
  • Step 2
  • Compound [II-12] obtained in Production method 2-4, Step 1 is cyclized using an agent for condensation, such as polyphosphoric acid and the like, in a hydrocarbon solvent, such as benzene, toluene, hexane, xylene and the like, under heating to give compound [II-13].
  • Step 3
  • Compound [II-13] obtained in Production method 2-4, Step 2 is subjected to catalytic reduction in the same manner as in Production method 1-4, Step 4 to give compounds [II-14] and [II-15].
  • Examples of the solvent include, besides alcohol solvents, ether solvents such as 1,4-dioxane, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran and the like and a mixed solvent thereof and the like.
  • Production Method 2-5
  • According to this production method, a carboxy-protecting group is eliminiated from a compound.
    Figure US20060030565A1-20060209-C00024
    wherein ring B, R4, X and Z are as defined above.
  • The carboxy-protecting group can be eliminated by a conventional deprotection method depending on the kind of protecting group.
  • For example, when Z is methyl, compound [II-16] is reacted in an alcohol solvent, such as methanol, ethanol, n-propanol, isopropanol and the like, in the presence of a base, such as potassium carbonate, sodium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide and the like, under heating for-deprotection, and the resulting solution is acidified to give compound [II].
  • Production Method 3
  • According to this production method, amine compound and carboxylic acid compound are condensed to amine.
    Figure US20060030565A1-20060209-C00025
    wherein ring A, ring B, R1, R2, R3, R4 and X are as defined above.
  • Compound [I] obtained in Production method 1 or a commercially available reagent and compound [II] obtained in Production method 2 or a commercially available reagent are condensed by a conventional method of formation of amide by condensation.
  • For example, compound [II] is treated with a halogenating agent, such as oxalyl chloride, thionyl chloride, phosphorus oxychloride, phosphorus pentachloride and the like, in a solvent at room temperature to give the corresponding acid chloride. Then, the compound is condensed with compound [I] in the presence of a tertiary amine, such as triethylamine and the like, or pyridine at room temperature or under cooling to give compound [1].
  • Examples of preferable solvent include halogen solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; ether solvents such as 1,4-dioxane, diethyl ether, 1,2-dimethaxyethane, tetrahydrofuran and the like.
  • Alternatively, compound [I] and compound [II] are reacted in a solvent in the presence of an agent for condensation at room temperature to give compound [1]. For smooth reaction, an enhancer may be used.
  • Examples of the agent for condensation include N,N′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide, N,N′-diisopropylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and the like and examples of the enhancer include hydroxysuccinimide, 1-hydroxybenzotriazole and the like.
  • Examples of preferable solvent include a hydrocarbon solvent such as benzene, toluene, hexane, xylene and the like; a halogen solvent such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane and the like; an ether solvent such as 1,4-dioxane, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran and the like; a polar solvent such as dimethylformamide, dimethyl sulfoxide, acetonitrile and the like; and a mixed solvent thereof.
  • For an improvement of the yield, reduction of cost and the like to lead to higher production efficiency, reduction, deprotection and the like may be carried out after formation of amide by condensation.
  • For example, when compound [I] or compound [II] has a nitro group, the nitro group may be reduced after formation of amide by condensation, or when compound [I] and compound [II] have a functional group such as hydroxy and the like, deprotection may be carried out after formation of amide by condensation.
  • Alternatively, methoxycarbonyl-substituted compound obtained in Production method 1-3 and Production method 3 is added to-an ether solvent, such as 1,4-dioxane, diethyl ether, 1,2-dimethoxyethane, tetrahydrofuran and the like, and lithium tetrahydroborate is added by portions in an argon stream under cooling for reduction to give hydroxymethyl-substituted compound.
    • EXAMPLES
  • The compound of the formula [1] of the present invention and the production method thereof are specifically explained in the following by way of examples. It is needless to say that the present invention is not limited to these examples.
    • Preparation Example 1-1 Synthesis of 4,6-diamino-2-methylquinoline
  • The synthesis was carried out according to a reference publication (Journal of the American Chemical Society, 70, 4065, 1948).
  • Step 1
  • 4-Aminoacetoanilide (150.2 g, 1 mol) was added to a solution of methyl acetoacetate (136.8 g, 1.1 mol) in methanol (450 ml) and the mixture was refluxed under heating for 17 hours. The reaction vessel was cooled to 0° C. and the resulting white precipitate was collected by filtration to give methyl β-(p-acetamidophenylamino)crotonate (231.5 g, 93%, white crystals).
  • Step 2
  • Methyl β-(p-acetamidophenylamino)crotonate (231.5 g, 0.93 mol) obtained in Preparation Example 1-1, Step 1 was added by small portions to Dowtherm A (trademark, 600 ml) which underwent refluxing under heating. The mixture was refluxed under heating for 10 minutes and the reaction mixture was cooled to room temperature. The resulting precipitate was collected by filtration and washed with ethyl acetate. The obtained crude crystals were suspended in methanol and collected by filtration to give N-(4-hydroxy-2-methyl-6-quinolyl)acetamide (178.3 g, 88%, deep yellow. crystals).
  • Step 3
  • To a suspension of N-(4-hydroxy-2-methyl-6-quinolyl)acetamide (100 g, 0.46 mol) obtained in Preparation Example 1-1, Step 2 in toluene (490 ml) was added dimethyl sulfate (75 ml, 0.79 mol) and the mixture was refluxed under heating for 8 hr. The resulting precipitate was collected by filtration, dissolved in water (1350 ml) and heated to 70° C. The solution was filtered and 35% aqueous sodium hydroxide solution (100 ml) was added to the filtrate. The resulting precipitate was collected by filtration to give N-(4-methoxy-2-methyl-6-quinolyl)acetamide (55.3 g, 52%, pale-brown crystals).
  • Step 4
  • N-(4-Methoxy-2-methyl-6-quinolyl)acetamide (55.6 g, 0.24 mol) obtained in Preparation Example 1-1, Step 3 was mixed with ammonium acetate (279.4 g, 3.62 mol) and the mixture was stirred under heating at 135° C. for 4 hours. To the reaction mixture were added water (280 ml) and conc. hydrochloric acid (450 ml) and the mixture was stirred under heating at 90° C. for 5 hr. The reaction mixture was cooled to 0° C. and the resulting precipitate was collected by filtration. The obtained crystals were dissolved in hot water and treated with active charcoal and filtered. To the filtrate was added 35% aqueous sodium hydroxide solution while cooling with ice. The resulting precipitate was collected by filtration, washed with water and dried under reduced pressure at 100° C. to give the title compound (28.4 g, 68%, pale-yellow crystals).
    • Preparation Example 1-2 Synthesis of 4,6-diamino-2-methylquinoline
  • Step 1
  • To 5-nitroisatin (19.21 g, 0.1 mol) were added acetone (36.7 ml, 0.5 mol) and aqueous ammonia (100 ml) and the mixture was heated in an autoclave at 100° C. for 12 hr. The reaction mixture was cooled to room temperature and the resulting crystals were collected by filtration and washed with water. The obtained crystals were dried by heating under reduced pressure to give 2-methyl-6-nitroquinoline-4-carboxamide (18.30 g, 79%).
  • Step 2
  • To 2-methyl-6-nitroquinoline-4-carboxamide (231 mg, 1 mmol) obtained in Preparation Example 1-2, Step 1 was added an aqueous sodium hypochlorite solution (0.851 ml,1.2 mmol) and the mixture was stirred at 0° C. for 2.5 hr. The reaction mixture was added dropwise to hot water (10 ml) under reflux with heating and the mixture was refluxed under heating for 20 min. The reaction mixture was cooled to room temperature and the resulting crystals were collected by filtration and dried by heating under reduced pressure to give 4-amino-2-methyl-6-nitroquinoline (177 mg, 87%).
  • Step 3
  • 4-Amino-2-methyl-6-nitroquinoline (337 mg, 1.7 mmol) obtained in the same manner as in Preparation Example 1-2, Step 2 was dissolved in methanol (15 ml) and thereto was added 10% palladium carbon (200 mg) and the mixture was stirred at room temperature at 3 atm under a hydrogen atmosphere for 15 hr. The reaction mixture was filtered through celite by suction and the filtrate was concentrated under reduced pressure to give the title compound (200 mg, 70%).
    • Preparation Example 1-3 Synthesis of 6-amino-2-methyl-4-methylaminoquinoline
  • Step 1
  • N-(4-Hydroxy-2-methyl-6-quinolyl)acetamide (4.32 g, 20 mmol) and phosphorus oxychloride (9.32 ml, 100 mmol) were heated at 100° C. for 15 min. The reaction mixture was cooled to room temperature and poured into ice water. Thereto was added 28% aqueous ammonia to make the solution alkaline. The resulting insoluble matter was collected by filtration, washed with ether and water, dried under reduced pressure at 80° C. to give N-(4-chloro-2-methyl-6-quinolyl)acetamide (6.85 g, crude, yellow solid).
  • Step 2
  • A suspension of N-(4-chloro-2-methyl-6-quinolyl)acetamide (4.0 g, crude) obtained in Preparation Example 1-3, Step 1 and 85% potassium hydroxide (6.6 g, 100 mmol) in N-methylformamide (100 ml) was heated at 170° C. for 3 hr 20 min. The reaction mixture was cooled to room temperature and the reaction mixture was diluted with chloroform and water. The chloroform layer was washed successively with saturated aqueous sodium hydrogencarbonate solution, water and saturated brine, dried over sodium sulfate and concentrated under reduced pressure. The obtained black oil was purified by silica gel column chromatography (chloroform:methanol=85:15→chloroform:methanol:28% aqueous ammonia=85:15:0.1) to give N-(2-methyl-4-methylamino-6-quinolyl)acetamide (255 mg, 9.5% from N-(4-hydroxy-2-methyl-6-quinolyl)acetamide) as a pale-brown solid.
  • Step 3
  • N-(2-Methyl-4-methylamino-6-quinolyl)acetamide (248 mg, 1.08 mmol) obtained in Preparation Example 1-3, Step 2 was refluxed under heating for 2 hr in 6N hydrochloric acid (10 ml). The reaction mixture was cooled to room temperature and 4N aqueous sodium hydroxide solution was added to make the pH not lower than 13, followed by ice-cooling. The resulting insoluble matter was collected by filtration and dried under reduced pressure at 60° C. to give the title compound (202 mg, 99.7%, pale-yellow solid).
    • Preparation Example 1-4 Synthesis of 4,6-diaminoquinoline dihydrobromide
  • The syntheses from Step 2 to Step 4 followed the method of a reference publication (Yakugaku Zasshi, 72, 665, 1952).
  • Step 1
  • A suspension of 4-nitroquinoline N-oxide (10 g, 52.5 mmol) and metal iron (26.4 g, 0.47 mol) in acetic acid (500 ml) was stirred under heating at 110° C. for 3 hr. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. To the residue was added an aqueous sodium hydroxide solution to make the solution alkaline, which was followed by extraction with chloroform (50 ml×6). The organic layer was washed with water and saturated brine, dried over sodium sulfate and concentrated under reduced pressure to give 4-aminoquinoline (6.0 g, 79%, brown crystals).
  • Step 2
  • To a solution of 4-aminoquinoline (2.28 g, 15.8 mmol) obtained in Preparation Example 1-4, Step 1 in acetic acid (30 ml) was added bromine (2.78 g, 17.4 mmol) with stirring under ice-cooling and the mixture was stirred at room temperature for 30 min. Diethyl ether was added and the resulting precipitate was collected by filtration to give 4-amino-3-bromoquinoline hydrobromide (4.39 g, 91%). The obtained crystals were dissolved in water and 1N aqueous sodium hydroxide solution was added to make the solution alkaline. The resulting precipitate was collected by filtration, washed with water and dried under reduced pressure to give 4-amino-3-bromoquinoline (2.91 g, 82%, pale-gray crystals).
  • Step 3
  • To a solution of 4-amino-3-bromoquinoline (2.90 g, 13 mmol) obtained in Preparation Example 1-4, Step 2 in conc. sulfuric acid (25 ml) was added 60% nitric acid (1.5 ml, 20 mmol) with stirring under ice-cooling, and the mixture was stirred for 1 hr. To the reaction mixture was added sodium hydroxide (40 g) under ice-cooling and the resulting precipitate was collected by filtration. The obtained crystals were dissolved in acetone, treated with active charcoal and recrystallized to give 4-amino-3-bromo-6-nitroquinoline (1.65 g, 47%, yellow crystals).
  • Step 4
  • To a solution of 4-amino-3-bromo-6-nitroquinoline (0.82 g, 3.05 mmol) obtained in Preparation Example 1-4, Step 3 in ethanol (30 ml) were added 25% hydrogen bromide-acetic acid solution (0.7 ml, 3.05 mmol) and 10% palladium carbon catalyst and the mixture was subjected to catalytic reduction at room temperature for 6 hr. The catalyst was filtered off and washed with water. The filtrate was concentrated under reduced pressure. The obtained residue was recrystallized from water-ethanol-ethyl acetate to give the title compound (0.92 g, 94%, green brown crystals).
    • Preparation Example 1-5 Synthesis of 1,7-diaminoisoquinoline
  • Step 1
  • Conc. sulfuric acid (80 ml) was added by small portions to tetrahydroisoquinoline (24.4 g, 183 mmol) under ice-cooling for dissolution. Then, 60% nitric acid (18 ml) was added dropwise from a funnel and the mixture was stirred under ice-cooling for 3 hr. The mixture was stirred at room temperature for 18 hr. The reaction mixture was diluted with water under ice-cooling, and 35% aqueous sodium hydroxide solution was added to adjust the solution to pH 12. After extraction with chloroform, the organic layer was washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was dissolved in ethanol (180 ml) and conc. hydrochloric acid (20 ml) was added under ice-cooling. The precipitated brown crystals were collected by filtration with suction to give 7-nitrotetrahydroisoquinoline hydrochloride (7.18 g, 22%).
  • Step 2
  • To 7-nitrotetrahydroisoquinoline hydrochloride (7.18 g, 33 mmol) obtained in Preparation Example 1-5, Step 1 was added Fremy's salt (100 g, 280 mmol) in 4% aqueous sodium carbonate solution(1.5 L). The mixture was stirred at room temperature for 7 days and the reaction mixture was extracted with chloroform, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by neutral alumina column chromatography (hexane:ethyl acetate=3:2) to give 7-nitroisoquinoline (3.21 g, 55%).
  • Step 3
  • To a solution of 7-nitroisoquinoline (2.38 g, 14 mmol) obtained in Preparation Example 1-5, Step 2 in chloroform (68 ml) was added m-chloroperbenzoic acid (3.54 g, 21 mmol). The mixture was stirred at room temperature for 21 hr. The insoluble matter in chloroform was filtered off with suction and washed with chloroform. The filtrate was washed with aqueous sodium hydrogencarbonate solution and saturated brine, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 7-nitroisoquinoline N-oxide. The obtained compound was used in the next reaction without purification.
  • Step 4
  • To a suspension of 7-nitroisoquinoline N-oxide obtained in Preparation Example 1-5, Step 3 in toluene (185 ml) was added phosphorus oxychloride (3.5 ml, 37 mmol), and the mixture was stirred under heating at 90° C. for 2 hr. The reaction mixture was cooled to room temperature and the reaction mixture was poured into an aqueous sodium hydrogencarbonate solution. The aqueous layer was extracted with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:acetone=30:1) to give 1-chloro-7-nitroisoquinoline (540 mg, 14%).
  • Step 5
  • To a suspension of 1-chloro-7-nitroisoquinoline (670 mg, 3.21 mmol) obtained in Preparation Example 1-5, Step 4 in methanol (100 ml) was added a 1M solution (6.5 ml, 6.5 mmol) of sodium methoxide. The mixture was refluxed under heating for 3 hr and concentrated under reduced pressure. The residue was dissolved in ethyl acetate, washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform:acetone=30:1) to give 1-methoxy-7-nitroisoquinoline (530 mg, 81%).
  • Step 6
  • A mixture of 1-methoxy-7-nitroisoquinoline (530 mg, 2.60 mmol) obtained in Preparation Example 1-5, Step 5 and ammonium acetate (3 g, 39.0 mmol) was stirred under, heating at 135° C. for A hr. The reaction mixture was added to aqueous sodium hydrogencarbonate solution and extracted with chloroform. The organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=2:3) to give 1-amino-7-nitroisoquinoline (246 mg, 50%).
  • Step 7
  • A mixture of 1-amino-7-nitroisoquinoline (246 mg, 1.3 mmol) obtained in Preparation Example 1-5, Step 6 and 5% palladium carbon (100 mg) in methanol (100 ml) was stirred at room temperature and normal pressure under a hydrogen atmosphere for 8 hr. The reaction mixture was filtered through celite by suction and the filtrate was concentrated under reduced pressure to give the title compound (203 mg, 99%).
    • Preparation Example 1-6 Synthesis of 7,9-diamino-1,2,3,4-tetrahydroacridine
  • Step 1
  • To a mixture of 5-nitroanthranilonitrile (1.63 g, 10 mmol) and cyclohexanone (10.3 ml, 100 mmol) was added zinc chloride (1.36 g, 10 mmol) and the mixture was refluxed under heating for 20 min. The reaction mixture was cooled to room temperature and diluted with ethyl acetate, and the insoluble matter was filtered off. The filtrate was concentrated under reduced pressure and chloroform was added to the obtained brown oil. The resulting yellow precipitate was collected by filtration and dried under reduced pressure at 80° C. This solid (1.56 g) was diluted with ethyl acetate and 1N aqueous sodium hydroxide solution, and ether was added. The insoluble matter was collected by filtration and dried under reduced pressure at 80° C. to give 9-amino-7-nitro-1,2,3,4-tetrahydroacridine (810 mg, 33%) as a yellow solid.
  • Step 2
  • 9-Amino-7-nitro-1,2,3,4-tetrahydroacridine (773 mg, 3.18 mmol) obtained in Preparation Example 1-6, Step 1 was dissolved in a mixed solvent of tetrahydrofuran (5 ml) and ethanol (5 ml) and 5% palladium carbon (500 mg) was added, which was followed by hydrogenation at room temperature and under normal pressure. After 7 hr, the reaction mixture was passed through celite and the filtrate was concentrated to give the title compound (665 mg, 98%) as a yellow oil.
    • Preparation Example 2-1 Synthesis of 2-[(4-ethylphenoxy)methyl]benzoic acid
  • Step 1
  • To a solution of methyl o-toluate (15.0 g, 0.1 mol) in carbon tetrachloride (200 ml) were added N-bromosuccinimide (18.7 g, 0.1 mol) and benzoyl peroxide (catalytic amount) and the mixture was refluxed under heating for 2 hr. The reaction mixture was cooled to room temperature and the resulting precipitate was filtered off. The filtrate was concentrated under reduced pressure to give methyl α-bromo-o-toluate (yellow oil). The obtained oil was used in the next reaction without purification.
  • Step 2
  • To a solution of methyl α-bromo-o-toluate (2.29 g, 10 mmol) obtained in Preparation Example 2-1, Step 1 and 4-ethylphenol (1.28 g, 10.5 mmol) in dimethylformamide (50 ml) was added potassium carbonate (4.15 g, 30 mmol) and the mixture was stirred under heating at 100° C. for 1 hr. The reaction mixture was added to ethyl acetate (100 ml) and washed with water and saturated brine. The organic layer was dried over sodium sulfate and the solvent was evaporated under reduced pressure. The crude product was purified by silica gel column chromatography (hexane:ethyl acetate=100:5) to give methyl 2-[(4-ethylphenoxy)methyl]benzoate (1.96 g, 73%)
  • Step 3
  • To a solution of methyl 2-[(4-ethylphenoxy)methyl]benzoate (1.96 g, 7.3 mmol) obtained in Preparation Example 2-1, Step 2 in ethanol (20 ml) was added 2N aqueous potassium hydroxide solution (11 ml, 21.8 mmol) and the mixture was stirred under reflux with heating for 2 hr. To the reaction mixture were added water (70 ml) and 6N hydrochloric acid (5 ml) and the resulting precipitate was collected by filtration and washed with water. The obtained solid was dried under reduced pressure to give the title compound (1.75 g, 94%, white crystals).
    • Preparation Example 2-2 Synthesis of 2-chloro-4-ethylphenol
  • A solution of 4-ethylphenol (25.4 g, 0.21 mol) and sulfuryl chloride (18.5 ml, 0.23 mol) in carbon tetrachloride (40 ml) was stirred under heating at 70° C. for 3 hr. The reaction mixture was diluted with chloroform and washed with water. The organic layer was dried over magnesium sulfate and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=9:1) to give 2-chloro-4-ethylphenol (25.1 g, 77%).
    • Preparation Example 2-3 Synthesis of 4-methylsulfonylphenol
  • Step 1
  • To a solution of anisole (3.3 ml, 30 mmol) in tetrachloroethylene (30 ml) was added methanesulfonic anhydride (5.75 g, 33 mmol) and the mixture was stirred under heating at 145° C. for 18 hr. Water was added to the reaction mixture and the mixture was extracted with diethyl ether. The organic layer was washed with saturated brine and dried over magnesium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=1:1) and the obtained crystals were recrystallized twice from hexane-ethyl acetate to give 4-methylsulfonylanisole (505 mg, 9%, colorless crystals).
  • Step 2
  • To 4-methylsulfonylanisole (505 mg, 2.7 mmol) obtained in Preparation Example 2-3, Step 1 was added 48% aqueous hydrogen bromide (3 ml), and the mixture was refluxed under heating for 10 hr. Water was added to the reaction mixture and the mixture was extracted with chloroform. The organic layer was dried over magnesium sulfate and the solvent was evaporated under reduced pressure to give the title compound (256 mg, 55%, colorless crystals). The obtained compound was used in the next reaction without purification.
    • Preparation Example 2-4 Synthesis of methyl 2-((5-benzofuranyloxy)methyl]benzoate and methyl 2-[(2,3-dihydrobenzofuran-5-yloxy)methyl]benzoate
  • Step 1
  • To a solution of 4-(benzyloxy)phenol (10.01 g, 50 mmol) and bromoacetaldehyde diethyl acetal (7.52 ml, 50 mmol) in dimethylformamide (100 ml) was added potassium carbonate (10.37 g, 75 mmol) and the mixture was heated at 170° C.
  • After 2.5 hr, the reaction mixture was cooled to room temperature. The mixture was diluted with water and ethyl acetate, and aqueous layer was removed. The organic layer was washed with saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography.(hexane:ethyl acetate=9:1) to give 2-[4-(benzyloxy)phenoxy]acetaldehyde diethyl acetal (11.902 g, 75%, pale-brown oil).
  • Step 2
  • 2-[4-(Benzyloxy)phenoxy]acetaldehyde diethyl acetal (3.16 g, 10 mmol) obtained in Preparation Example 2-4, Step 1 and polyphosphoric acid (3.16 g) were heated in toluene (30 ml) at 100° C. After 40 min, the mixture was cooled to room temperature. The reaction mixture was diluted with ether and supernatant was separated by decantation. The supernatant was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (hexane:ethyl acetate=20:1) to give 5-(benzyloxy)benzofuran (1.032 g, 46%, pale-yellow oil).
  • Step 3
  • 5-(Benzyloxy)benzofuran (1.02 g, 4.55 mmol) obtained in Preparation Example 2-4, Step 2 was dissolved in a mixed solvent of ethanol (5 ml) and ethyl acetate (5 ml) and 5% palladium carbon (500 mg) was added, which was followed by hydrogenation at room temperature under normal pressure. After 2 hr, the reaction mixture was passed through celite and the filtrate was concentrated under reduced pressure. The residue was dissolved in dimethylformamide (20 ml) and methyl α-bromo-o-toluate (1.042 g, 4.55 mmol) and potassium carbonate (1.26 g, 9.10 mmol) were added. The mixture was heated at 100° C. for 1.25 hr and cooled to room temperature. The reaction mixture was diluted with water and ethyl acetate to separate the layers. The organic layer was washed with saturated aqueous sodium hydrogencarbonate solution and saturated brine, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane:ethyl acetate=9:1) to give methyl 2-[(5-benzofuranyloxy)methyl]benzoate (352 mg, 27%, white crystals) and methyl 2-[(2,3-dihydrobenzofuran-5-yloxy)methyl]benzoate (220 mg, 17%, pale-yellow oil).
    • Example 1 Synthesis of N-(4-amino-2-methyl-6-quinolyl)-2-[(4-ethylphenoxy)methyl]benzamide hydrochloride
  • To a solution of 2-[(4-ethylphenoxy)methyl]benzoic acid (1.13 g, 4.4 mmol) obtained in Preparation Example 2-1 in chloroform (20 ml) was added oxalyl chloride (0.6 ml, 6.8 mmol) and the mixture was stirred at room temperature for 1 hr. Then the reaction mixture was concentrated under reduced pressure. To the obtained acid chloride were added pyridine (20 ml) and 4,6-diamino-2-methylquinoline (623 mg, 4 mmol) obtained in Preparation Example 1-1 and the mixture was stirred at room temperature for 10 hr. To the reaction mixture was added an aqueous sodium hydrogencarbonate solution and the mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated brine and dried over sodium sulfate, and the solvent was evaporated. The obtained crude product was dissolved in ethanol and treated with active charcoal, and the solvent was evaporated. The obtained residue was dissolved in ethyl acetate and 1N hydrochloric acid—ether solution was added. The resulting precipitate was collected by filtration. The obtained solid was heated and dried under reduced pressure to give the title compound (1.06 g, 59%, pale-yellow crystals).
  • Elemental analysis for C26H25N3O2.HCl Calculated; C: 69.71%, H: 5.85%, N: 9.38% Found; C: 69.77%, H: 5.78%, N: 9.41% Melting point: 235° C.
    • Example 131 Synthesis of N-(4-amino-2-hydroxymethyl-6-quinolyl)-2-[(4-methylphenoxy)-methyl]benzamide hydrochloride
  • Step 1
  • A solution of 4-nitroaniline (6.91 g, 50 mmol) and dimethyl-acetylenedicarboxylate (7.82 g, 55 mmol) in methanol (100 ml) was refluxed under heating for 24.5 hr. The reaction vessel was cooled to room temperature and allowed to stand for a day. The resulting crystals were collected by filtration to give dimethyl 2-[(4-nitrophenyl)amino]-2-butenedioate (6.43 g, 46%, yellow crystals).
  • Step 2
  • To Dowtherm A (trademark, 30 ml) refluxed under heating was added dimethyl 2-[(4-nitrophenyl)amino]-2-butenedioate (6.32 g, 22.6 mmol) obtained in Example 131, Step 1 over 5 min by small portions. The mixture was refluxed under heating for 25 min and the reaction mixture was cooled to room temperature. The reaction mixture was diluted with ether and the resulting precipitate was filtrated. The obtained crude crystals were suspended in methanol and collected by filtration to give methyl 1,4-dihydro-6-nitro-4-oxo-2-quinolinecarboxylate (4.75 g, 85%, dark brown crystals).
  • Step 3
  • To a suspension of methyl 1,4-dihydro-6-nitro-4-oxo-2-quinolinecarboxylate (3.72 g, 15 mmol) obtained in Example 131, Step 2 in acetonitrile (50 ml) was added chlorosulfonyl isocyanate (1.30 ml, 15 mol) and the mixture was refluxed under heating for 1 hr. The reaction mixture was cooled to room temperature and methanol was added, which was followed by concentration under reduced pressure. To the residue was added 2 mol/l aqueous sodium carbonate solution to allow suspending and the insoluble matter was collected by filtration. The insoluble matter was dried under reduced pressure at 80° C. to give methyl 4-amino-6-nitro-2-quinolinecarboxylate as crude brown crystals (3.23 g). This compound was used in the next reaction without purification.
  • Step 4
  • A suspension of crude crystals (494 mg) of methyl 4-amino-6-nitro-2-quinolinecarboxylate obtained Example 131, Step 3 and 5% palladium carbon (500 mg) in ethanol (10 ml) was hydrogenated at room temperature under normal pressure. After 2.5 hr, the reaction mixture was passed through celite. The filtrate was concentrated under reduced pressure to give a crude product of methyl 4,6-diamino-2-quinolinecarboxylate (275 mg, yellow foam-like solid). This compound was used in the next reaction without purification.
  • Step 5
  • The crude product (270 mg) of methyl 4,6-diamino-2-quinolinecarboxylate obtained in Example 131, Step 4 and 2-[(4-methylphenoxy)methyl]benzoic acid (363 mg, 1.5 mmol) obtained in the same manner as in Preparation Example 2-1 were condensed to amide in the same manner as in Example 1 to give N-(4-amino-2-methoxycarbonyl-6-quinolyl)-2-[(4-methylphenoxy)methyl]benzamide (175 mg, 17% from methyl 1,4-dihydro-6-nitro-4-oxo-2-quinolinecarboxylate) as a yellow solid.
  • Step 6
  • To a solution of N-(4-amino-2-methoxycarbonyl-6-quinolyl)-2-[(4-methylphenoxy)methyl]benzamide (170 mg, 0.385 mmol) obtained in Example 131, Step 5 in tetrahydrofuran (10 ml) was added, by small portions, lithium tetrahydroboroate (42 mg, 1.927 mmol) under ice-cooling in an argon stream. After 10 min, the mixture was warmed to room temperature and the mixture was stirred for 2 hr. The reaction mixture was diluted with saturated brine and ethyl acetate to separate the layers. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained yellow residue was dissolved in ethyl acetate and 4N hydrochloric acid—dioxane solution (0.5 ml) was added to precipitate hydrochloride. This salt was collected by filtration and dried under reduced pressure at 80° C. to give the title compound (116 mg, 67%, pale-yellow crystals).
  • An amino-substituted compound obtained in the same manner as in Preparation Examples 1-1 to 1-6 or a commercially available amino-substituted compound and carboxylic acid derivative obtained in the same manner as in Preparation Examples 2-1 to 2-4 or a commercially available carboxylic acid derivative were treated in the same manner as in Example 1 or 131 to give the compounds of Example 2 to Example 130 and Example 132. The property values are shown in Table 1 to Table 44.
    • Example 133 Synthesis of N-(4-amino-2-methyl-6-quinolyl)-2-[(4-ethylphenoxy)methyl]benzamide hydrochloride monohydrate
  • To crude crystals of N-(4-amino-2-methyl-6-quinolyl)-2-[(4-ethyl-phenoxy)methyl]benzamide hydrochloride (24.0 g, 53.7 mmol) obtained in the same manner as in Example 1 was added ethanol (120 ml) and the mixture was heated to 55-60° C. for dissolution. This solution was filtrated and to the filtrate was dropwise added water (120 ml) with stirring under heating at 55-60° C. This reaction mixture was cooled to room temperature and the resulting precipitate was filtrated. The obtained solid was dried at 1 mmHg and 60° C. for 3 days to give the title compound (22.6 g, 94%, colorless crystals).
  • Elemental analysis for C26H25N3O2.HCl H2O Calculated; C: 67.02%, H: 6.06%, N: 9.02% Found; C: 66.64%, H: 6.06%, N: 8.99% Melting point: 130° C.
    TABLE 1
    Exp. No. Stuctural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    1
    Figure US20060030565A1-20060209-C00026
         		235° C. DMSO-d6, 300 MHz 1.10(3H, t, J=7.7 Hz) 2.48(2H, q, J=7.7 Hz) 2.59(3H, s) 5.30(2H, s) 6.61(1H, s) 6.84(2H, d, J=8.6 Hz) 7.05(2H, d, J=8.6 Hz) 7.48-7.69(4H, m) 7.94(2H, s) 8.66(2H, br. s) 8.74(1H, s) 10.86(1H, s) 13.93(1H, br. s) FAB−447 [M − H+](3)
    2
    Figure US20060030565A1-20060209-C00027
         		262° C. DMSO-d6.300 MHz
    3
    Figure US20060030565A1-20060209-C00028
         		245˜246° C. DMSO-d6,300 MHz 2.59(3H, s) 5.33(2H, s) 6.60(1H, s) 6.87-6.95(3H, m) 7.21-7.26(2H, m) 7.51-7.70(4H, m) 7.93(2H, s) 8.66(2H, br. s) 8.75(1H, s) FAB- 418 [M − H]- (83) 367 (100)
  • TABLE 2
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    4
    Figure US20060030565A1-20060209-C00029
         		276° C. DMSO-d6,300 MHz 2.59(3H, s) 3.65(3H, s) 5.27(2H, s) 6.60(1H, s) 6.77-6.89(4H, m) 7.48-7.68(4H, m) 7.88-7.96(2H, m) 8.70(2H, br. s) 8.74(1H, s) 10.85(1H, s) 13.78(1H, s) FAB−448 [M − H]- (65) 367 (100)
    5
    Figure US20060030565A1-20060209-C00030
         		265° C. DMSO-d6,300 MHz
    6
    Figure US20060030565A1-20060209-C00031
         		270° C. DMSO-d6,300 MHz
  • TABLE 3
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    7
    Figure US20060030565A1-20060209-C00032
         		148° C. DMSO-d6,300 MHz
    8
    Figure US20060030565A1-20060209-C00033
         		196° C. DMSO-d6,300 MHz
    9
    Figure US20060030565A1-20060209-C00034
         		DMSO-d6,300 MHz 2.20(3H, s) 2.40(3H, s) 5.31(2H, s) 6.45(3H, s) 6.70-6.76(3H, m) 7.11(1H, t, J=7.2 Hz) 7.47-7.57(4H, m) 7.62-7.64(2H, m) 8.39(1H, s) 10.51(1H, s) FAB+398 [M + H+](100)
  • TABLE 4
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    10
    Figure US20060030565A1-20060209-C00035
         		DMSO-d6,300 MHz 2.59(3H, s) 3.62(6H, s) 5.29(2H, s) 6.04-6.08(3H, m) 6.60(1H, s) 7.49-7.69(4H, m) 7.89-7.97(2H, m) 8.65(2H, br. s) 8.76(1H, d, J=1.5 Hz) 10.85(1H, s) 13.74(1H, br. s) FAB−479 [M − H+](2)
    11
    Figure US20060030565A1-20060209-C00036
         		245° C. DMSO-d6,300 MHz 2.59(3H, s) 5.33(2H, s) 6.59(3H, s) 6.95(2H, d, J=8.9 Hz) 7.27(2H, d, J=8.9 Hz) 7.49-7.70(4H, m) 7.85-7.95(2H, m) 8.67(2H, br. s) 8.73(1H, s) FAB−454 [M − H]−(50) 453 (27) 452 (78) 416 (100)
    12
    Figure US20060030565A1-20060209-C00037
         		270° C. DMSO-d6,300 MHz 2.47(3H, s) 2.58(3H, s) 5.44(2H, s) 6.59(1H, s) 7.03(2H, d, J=8.9 Hz) 7.50-7.71(4H, m) 7.81-7.94(4H, m) 8.65(2H, br. s) 8.72(1H, s) 10.88(1H, s) FAB−460 [M − H]−(18) 459 (100)
  • TABLE 5
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    13
    Figure US20060030565A1-20060209-C00038
         		183.0˜184.0° C. DMSO-d6,300 MHz 2.58(3H, s) 5.22(2H, s) 6.59(1H, s) 6.61(2H, d, J=9.6 Hz) 6.76(2H, d, J=9.6 Hz) 7.50-7.65(4H, m) 7.89-7.99(2H, m) 8.59(2H, br. s) 8.74(1H, s) 8.94(1H, s) 10.83(1H, s) 13.78(1H, br. s)
    14
    Figure US20060030565A1-20060209-C00039
         		210.0˜212.0° C. DMSO-d6,300 MHz 2.59(3H, s) 5.05(2H, s) 5.28(2H, s) 6.60(1H, s) 6.88(4H, s) 7.50-7.69(4H, m) 7.93(2H, s) 8.61(2H, s) 8.73(1H, s) 10.86(1H, s) 13.91(1H, br. s) FAB−479 [M − H+](3)
    15
    Figure US20060030565A1-20060209-C00040
         		224° C. DMSO-d6,300 MHz
  • TABLE 6
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    16
    Figure US20060030565A1-20060209-C00041
         		286° C. DMSO-d6,300 MHz
    17
    Figure US20060030565A1-20060209-C00042
         		255° C. DMSO-d6,300 MHz 2.18(3H, s) 2.59(3H, s) 5.29(2H, s) 6.60(1H, s) 6.82(2H, d, J=8.4 Hz) 7.02(2H, d, J=8.4 Hz) 7.48-7.88(6H, m) 8.66(2H, br. s) 8.74(1H, s) 10.85(1H, s) 13.81(1H, s) FAB−432 [M − H]−(8) 107 (100)
    18
    Figure US20060030565A1-20060209-C00043
         		220° C. DMSO-d6,300 MHz 2.60(3H, s) 5.44(2H, s) 6.61(1H, s) 7.13(2H, d, J=8.7 Hz) 7.53-7.72(6H, m) 7.95(2H, s) 8.69(2H, br. s) 8.72(1H, s) FAB−486 [M − H]−(7) 161 (100)
  • TABLE 7
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    19
    Figure US20060030565A1-20060209-C00044
         		245° C. DMSO-d6,300 MHz 2.59(3H, s) 5.48(2H, s) 6.59(1H, s) 7.44-7.77(8H, m) 7.84-7.93(2H, m) 8.65(2H, br. s) 8.73(1H, s)
    20
    Figure US20060030565A1-20060209-C00045
         		200.0˜203.0° C. DMSO-d6,300 MHz 2.60(3H, s) 5.55(2H, s) 6.62(1H, s) 7.10(1H, t, J=8.2 Hz) 7.42(1H, d, j=8.2 Hz) 7.55-7.86(6H, m) 7.95(2H, s) 8.73(2H, br. s) 8.74(1H, s) 10.91(1H, s) 13.99(1H, br. s) FAB−464 [M − H+](4)
    21
    Figure US20060030565A1-20060209-C00046
         		154.0˜155.0° C. DMSO-d6,300 MHz 2.21(3H, s) 2.59(3H, s) 5.33(2H, s) 6.60(1H, s) 6.93-7.00(4H, m) 7.50-7.70(4H, m) 7.90(1H, d, J=9.2 Hz) 7.94(1H, d, J=9.2 Hz) 8.63(2H, br. s) 8.74(1H, s) 10.87(1H, s) 13.85(1H, br. s) FAB−477 [M − H+](1)
  • TABLE 8
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    22
    Figure US20060030565A1-20060209-C00047
         		148.0˜149.0° C. DMSO-d6,300 MHz 2.59(3H, s) 3.65(3H, s) 5.32(2H, s) 6.60(1H, s) 6.82-6.98(4H, m) 7.51-7.58(2H, m) 7.66-7.71(2H, m) 7.95(2H, s) 8.65(2H, br. s) 8.75(1H, s) 10.87(1H, s) 13.80(1H, br. s) FAB+449[M − H+](4)
    23
    Figure US20060030565A1-20060209-C00048
         		237° C. DMSO-d6,300 MHz
    24
    Figure US20060030565A1-20060209-C00049
         		147.0˜149.0° C. DMSO-d6,300 MHz 2.59(3H, s) 5.36(2H, s) 6.60(1H, s) 6.90-6.99(3H, m) 7.22-7.28(1H, m) 7.50-7.71(4H, m) 7.89-7.92(2H, m) 8.61(2H, br. s) 8.73(1H, s) 10.86(1H, s) 13.85(1H, br. s) FAB−455 [M − H+](5)
  • TABLE 9
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    25
    Figure US20060030565A1-20060209-C00050
         		146.0˜148.0° C. DMSO-d6,300 MHz 2.59(3H, s) 5.31(2H, s) 6.60(1H, s) 6.93-7.09(4H, m) 7.49-7.70(4H, m) 7.87-7.95(2H, m) 8.61(2H, br. s) 8.73(1H, s) 10.85(1H, s) 13.80(1H, br. s) FAB−437 [M − H+](3)
    26
    Figure US20060030565A1-20060209-C00051
         		223° C. DMSO-d6,300 MHz
    27
    Figure US20060030565A1-20060209-C00052
         		165° C. DMSO-d6,300 MHz
  • TABLE 10
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    28
    Figure US20060030565A1-20060209-C00053
         		233° C. DMSO-d6,300 MHz
    29
    Figure US20060030565A1-20060209-C00054
         		268° C. DMSO-d6,300 MHz
    30
    Figure US20060030565A1-20060209-C00055
         		268° C. DMSO-d6,300 MHz
  • TABLE 11
    Exp. No. Strucrural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    31
    Figure US20060030565A1-20060209-C00056
         		256° C. DMSO-d6,300 MHz
    31
    Figure US20060030565A1-20060209-C00057
         		238° C. DMSO-d6,300 MHz
    33
    Figure US20060030565A1-20060209-C00058
         		252° C. DMSO-d6,300 MHz
  • TABLE 12
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    34
    Figure US20060030565A1-20060209-C00059
         		140.0˜142.0° C. DMSO-d6,300 MHz 0.83(3H, t, J=7.4 Hz) 1.48(2H, q, J=7.4 Hz) 2.42(2H, t, J=7.4 Hz) 2.60(3H, s) 5.30(2H, s) 6.61(1H, s) 6.84(2H, d, J=8.5 Hz) 7.02(2H, d, J=8.5 Hz) 7.50-7.69(4H, m) 7.95(2H, s) 8.68(2H, br. s) 8.74(1H, s) 10.87(1H, s) 14.01(1H, br. s) FAB−461 [M − H+](6)
    35
    Figure US20060030565A1-20060209-C00060
         		255° C. DMSO-d6,300 MHz
    36
    Figure US20060030565A1-20060209-C00061
         		253° C. DMSO-d6,300 MHz
  • TABLE 13
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    37
    Figure US20060030565A1-20060209-C00062
         		262° C. DMSO-d6,300 MHz
    38
    Figure US20060030565A1-20060209-C00063
         		148.0˜150.0° C. DMSO-d6 2.39(3H, s) 5.33(2H, s) 6.39(2H, br. s) 6.44(1H, s) 6.81(2H, d, J=8.8 Hz) 7.49-7.67(8H, m) 8.36(1H, s) 10.49(1H, s) FAB+510 [M + H+](100)
    39
    Figure US20060030565A1-20060209-C00064
         		207° C. DMSO-d6,300 MHz 2.59(3H, s) 5.53(2H, s) 6.60(1H, s) 7.52-7.73(4H, m) 7.85-7.94(3H, m) 8.35(1H, m) 8.54(1H, s) 8.68(2H, br. s) 8.72(1H, s) 10.91(1H, s) 13.94(1H, s) FAB−419 [M − H]−(6) 367 (100)
  • TABLE 14
    Exp. No. Scructural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    40
    Figure US20060030565A1-20060209-C00065
         		225° C. DMSO-d6,300 MHz
    41
    Figure US20060030565A1-20060209-C00066
         		195° C. DMSO-d6,300 MHz
    42
    Figure US20060030565A1-20060209-C00067
         		150.0˜152.0° C. DMSO-d6 2.19(3H, s) 2.60(3H, s) 5.32(2H, s) 6.61(1H, s) 6.79(1H, dd, J=2.9, 8.7 Hz) 6.92(1H, d, J=2.9 Hz) 7.22(1H, d, J=8.7 Hz) 7.52-7.69(4H, m) 7.93(2H, s) 8.71(2H, br. s) 8.74(1H, s) 10.90(1H, s) 13.91(1H, s)
  • TABLE 15
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    43
    Figure US20060030565A1-20060209-C00068
         		159.0˜160.0° C. DMSO-d6 2.19(3H, s) 2.60(3H, s) 5.40(2H, s) 6.61(1H, s) 7.05(2H, s) 7.20(1H, s) 7.53-7.61(2H, m) 7.69-7.73(2H, m) 7.95(2H, s) 8.66(2H, br. s) 8.75(1H, s) 10.89(1H, s) 13.98(1H, br. s)
    44
    Figure US20060030565A1-20060209-C00069
         		96.0˜98.0° C. DMSO-d6 1.11(3H, t, J=7.6 Hz) 2.41(3H, s) 2.50(2H, q, J=7.6 Hz) 5.30(2H, s) 6.45(1H, s) 6.56(2H, br. s) 6.86(2H, d, J=8.6 Hz) 7.06(2H, d, J=8.6 Hz) 7.48-7.55(2H, m) 7.62-7.67(4H, m) 8.41(1H, s) 10.5(1H, s) FAB+411 [M + H+](100)
    45
    Figure US20060030565A1-20060209-C00070
         		DMSO-d6 2.21(3H, S) 2.40(3H, s) 5.32(2H, s) 6.44(2H, br. s) 6.81(1H, dd, J=2.7, 8.6 Hz) 6.95(1H, d, J=2.7 Hz) 7.24(1H, D, J=8.6 Hz) 7.47-7.67(6H, m) 8.38(1H, s) 10.5(1H, br. s) FAB+432 [M](100) 433 [M + 1](41)
  • TABLE 16
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    46
    Figure US20060030565A1-20060209-C00071
         		258° C. DMSO-d6,300 MHz 2.00(3H, s) 2.59(3H, s) 4.94(2H, s) 5.34(2H, s) 6.60(1H, s) 6.93(2H, d, J=8.6 Hz) 7.24(2H, d, J=8.6 Hz) 7.49-7.90(2H, m) 7.85-7.96(2H, m) 8.63(2H, br. s) 8.74(1H, s) FAB−490 [M − H]−(87) 454 (100)
    47
    Figure US20060030565A1-20060209-C00072
         		273° C. DMSO-d6,300 MHz 2.58(3H, s) 4.36(2H, d, J=5.2 Hz) 5.02(1H, t, J=5.2 Hz) 5.32(2H, s) 6.59(1H, s) 6.88(2H, d, J=8.6 Hz) 7.16(2H, d, J=8.6 Hz) 7.49-7.70(4H, m) 7.85-7.98(4H, m) 8.67(2H, Br, s) 8.75(1H, s) FAB−412 [M − H]−(100)
    48
    Figure US20060030565A1-20060209-C00073
         		154.0˜156.0° C. DMSO-d6,300 MHz 2.59(3H, s) 5.46(2H, s) 6.59(1H, s) 7.13-7.80(11H, m) 7.91-7.95(2H, m) 8.67(2H, br. s) 8.75(1H, s) 10.91(1H, s) 14.01(1H, br. s) FAB− 469 [M − H+] (2)
  • TABLE 17
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    49
    Figure US20060030565A1-20060209-C00074
         		247.0˜249.0° C. DMSO-d6 1.32(3H, t, J=7.7 Hz) 2.89(2H, q, J=7.7 Hz) 5.34(2H, s) 6.66(1H, s) 6.96(2H, d, J=9.2 Hz) 7.26(2H, d, J=4.8 Hz) 7.49-7.71(4H, m) 7.95(1H, d, J=8.8 Hz) 7.99(1H, d, J=9.2 Hz) 8.72(2H, br. s) 8.73(1H, s) 10.87(1H, s) 13.91(1H, s) FAB−467 [M − H+](3)
    50
    Figure US20060030565A1-20060209-C00075
         		232.0˜233.0° C. DMSO-d6 0.96(3H, t, J=7.4 Hz) 1.73-1.80(2H, m) 2.85(2H, t, J=7.4 Hz) 5.34(2H, s) 6.65(1H, s) 6.96(2H, d, J=8.8 Hz) 7.26(2H, d, J=8.8 Hz) 7.50-7.71(4H, m) 7.94(1H, d, J=9.2 Hz) 8.00(1H, d, J=9.2 Hz) 8.73(2H, br. s) 8.74(1H, s) 10.87(1H, s) 13.93(1H, s) FAB−481 [M − H+] (3)
    51
    Figure US20060030565A1-20060209-C00076
         		163° C. DMSO-d6,300 MHz 1.32(3H, t, J=7.5 Hz) 2.88(2H, q, J=7.5 Hz) 5.44(2H, s) 6.65(1H, s) 7.22(1H, d, J=8.9 Hz) 7.34(1H, dd, J=8.9, 2.5 Hz) 7.51(1H, d, J=2.5 Hz) 7.53-7.75(4H, m) 7.90-7.97(2H, m) 8.66(2H, br. s) 8.74(1H, s) 10.89(1H, s) 13.68(1H, s) FAB−502 (25) 500 (42) 127 (100)
  • TABLE 18
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    52
    Figure US20060030565A1-20060209-C00077
         		162.0˜164.0° C. DMSO-d6 1.35(6H, d, J=6.9 Hz) 3.22(1H, o, J=6.9 Hz) 5.34(2H, s) 6.69(1H, s) 6.96(2H, d, J=9.0 Hz) 7.26(2H, d, J=9.0 Hz) 7.52-7.68(4H, m) 7.68(1H, d, J=9.1 Hz) 8.04(1H, d, J=9.1 Hz) 8.73(1H, s) 8.73(2H, br. s) 10.9(1H, s) 13.7(1H, br. s) FAB−482 [M − H+](28)
    53
    Figure US20060030565A1-20060209-C00078
         		160.0˜161.0° C. DMSO-d6 1.10(3H, t, J=7.6 Hz) 1.32(3H, t, J=7.6 Hz) 2.48(2H, q, J=7.6 Hz) 2.89(2H, q, J=7.6 Hz) 5.30(2H, s) 6.66(1H, s) 6.84(2H, d, J=8.6 Hz) 7.05(2H, D, J=8.6 Hz) 7.51-7.69(4H, m) 7.96(2H, s) 8.74(2H, br. s) 8.75(1H, s) 10.9(1H, s) 13.8(1H, s) FAB−461 [M − H+](13)
    54
    Figure US20060030565A1-20060209-C00079
         		150.0˜152.0° C. DMSO-d6 1.32(3H, t, J=7.5 Hz) 2.19(3H, s) 2.89(2H, q, J=7.5 Hz) 5.32(2H, s) 6.66(1H, s) 6.79(1H, dd, J=3.0, 8.7 Hz) 6.92(1H, d, J=3.0 Hz) 7.22(1H, d, J=8.7 Hz) 7.50-7.70(4H, m) 7.91-7.99(2H, m) 8.73(2H, br. s) 8.74(1H, s) 10.86(1H, s) 13.85(1H, br. s) FAB−481 [M − H+](26)
  • TABLE 19
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    55
    Figure US20060030565A1-20060209-C00080
         		83.0˜84.0° C. DMSO-d6,300 MHz 2.41(3H, s) 4.53(2H, s) 4.78(2H, s) 6.46(1H, s) 6.49(2H, br. s) 7.22-7.30(5H, m) 7.45-7.66(6H, m) 8.41(1H, s) 10.45(1H, s) 398 [M + H+](100)
    56
    Figure US20060030565A1-20060209-C00081
         		DMSO-d6,300 MHz 2.91(3H, s) 5.33(2H, s) 6.87-6.92(3H, m) 7.18-7.23(2H, m) 7.52-7.68(4H, m) 7.87(1H, d, J=18.7 Hz) 8.18-8.25(2H, m) 8.79(1H, s) 8.92(1H, d, J=8.7 Hz) 11.05(1H, s)
    57
    Figure US20060030565A1-20060209-C00082
         		DMSO-d6,300 MHz 2.40(3H, s) 6.43(2H, br. s) 6.45(1H, s) 7.53-7.75(5H, m) 8.00(1H, s) 8.03(1H, s) 8.38(1H, d, J=2.1 Hz) 10.35(1H, s) FAB+278 [M + H+](100)
  • TABLE 20
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    58
    Figure US20060030565A1-20060209-C00083
         		DMSO-d6,300 MHz 2.37(3H, s) 6.36(2H, s) 6.42(1H, s) 7.29-7.61(11H, m) 8.25(1H, d, J=2.0 Hz) 10.33(1H, s) FAB+354 [M + H]+(100)
    59
    Figure US20060030565A1-20060209-C00084
         		DMSO-d6,300 MHz 2.44(3H, s) 6.49(1H, s) 6.68(2H, br. s) 7.56-8.30(7H, m) 10.30(1H, s) FAB+303 [M + H+](9)
    60
    Figure US20060030565A1-20060209-C00085
         		176° C.
  • TABLE 21
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    61
    Figure US20060030565A1-20060209-C00086
         		232° C.
    62
    Figure US20060030565A1-20060209-C00087
         		208° C.
    63
    Figure US20060030565A1-20060209-C00088
         		212° C.
  • TABLE 22
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    64
    Figure US20060030565A1-20060209-C00089
         		253° C.
    65
    Figure US20060030565A1-20060209-C00090
         		223.0˜225.0° C. DMSO-d6 1.20-1.38(6H, m) 1.50-1.68(4H, m) 2.57(3H, s) 2.78(2H, t, J=6.5 Hz) 3.79(2H, t, J=6.5 Hz) 6.59(1H, s) 6.81-6.91(3H, m) 7.22-7.51(6H, m) 7.88-7.94(2H, m) 8.69(2H, br. s) 8.79(1H, s) 10.78(1H, s) 13.79(1H, br. s)
    66
    Figure US20060030565A1-20060209-C00091
         		210° C.
  • TABLE 23
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    67
    Figure US20060030565A1-20060209-C00092
         		DMSO-d6,300 MHz 2.02(2H, m) 2.17 (3H, s) 2.61(3H, s) 2.94(3H, t, J=8.2 Hz) 3.90(3H, t, J=6.4 Hz) 6.62(1H, s) 6.71(2H, d, J=8.6 Hz) 6.97(2H, d, J=8.6 Hz) 7.34-7.54(4H, m) 7.95(2H, s) 8.50-8.90(2H, brs) 8.78(1H, s) 10.80(1H, s) 14.02(1H, s)
    68
    Figure US20060030565A1-20060209-C00093
         		DMSO-d6,300 MHz 2.07(2H, s) 2.61(3H, s) 2.97(2H, t, J=8.0 Hz) 4.04(2H, t, J=6.1 Hz) 6.62(1H, s) 7.07(1H, d, J=8.9 Hz) 7.25 7.34-7.53(5H, m) 8.50-8.90(2H, brs) 8.77(1H, s) 10.80(1H, s) 14.00(1H, s)
    69
    Figure US20060030565A1-20060209-C00094
         		DMSO-d6,300 MHz 2.60(3H, s) 3.24(2H, t, J=6.8 Hz) 4.23(3H, t, J=6.8 Hz) 6.62(1H, s) 6.90(2H, d, J=8.9 Hz) 7.23(2H, d, J=8.9 Hz) 7.39-7.60 (4H, m) 7.95(2H, s) 8.50-8.90(2H, brs) 8.80(1H, s) 10.85(1H, s) 13.94(1H, s)
  • TABLE 24
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    70
    Figure US20060030565A1-20060209-C00095
         		DMSO-d6,300 MHz 2.38(3H, s) 4.18(2H, s) 6.41(2H, s) 6.45(1H, s) 7.14-7.63(11H, m) 8.42(1H, s) 10.44(1H, s) FAB−366 [M − H]−(100)
    71
    Figure US20060030565A1-20060209-C00096
         		DMSO-d6,300 MHz 2.38(3H, s) 2.88-2.93(2H, m) 3.03-3.09(2H, m) 6.43(2H, s) 6.45(1H, s) 7.14-7.71(11H, m) 8.43(1H, s) 10.46(1H, s) FAB+382 [M + H]+(100)
    72
    Figure US20060030565A1-20060209-C00097
         		>300° C.
  • TABLE 25
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    73
    Figure US20060030565A1-20060209-C00098
         		280.0˜282.0° C.
    74
    Figure US20060030565A1-20060209-C00099
         		252.0˜254.0° C.
    75
    Figure US20060030565A1-20060209-C00100
         		306.0˜308.0° C.
  • TABLE 26
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    76
    Figure US20060030565A1-20060209-C00101
         		184.0˜185.0° C. 2.40(3H, s) 4.04(2H, s) 6.44(1H, s) 6.46(2H, br. s) 7.19-7.42(7H, m) 7.64(1H, d, J=9.3 Hz) 7.72(1H, dd, J=2.1, 9.0 Hz) 7.94(2H, d, J=7.8 Hz) 8.36(1H, d, J=2.1 Hz) 10.27(1H, s) FAB+368 [M + H+](100)
    77
    Figure US20060030565A1-20060209-C00102
         		183.0˜184.0° C. DMSO-d6,300 MHz 2.40(3H, s) 2.92-3.01(4H, m) 6.43(2H, br. s) 6.44(1H, s) 7.16-7.38(7H, m) 7.65(1H, d, J=8.9 Hz) 7.73(1H, dd, J=2.1, 8.9 Hz) 7.94(2H, d, J=8.1 Hz) 8.37(1H, d, J=2.1 Hz) 10.28(1H, s) FAB+382 [M + H+](100)
    78
    Figure US20060030565A1-20060209-C00103
         		161.0˜162.0° C. DMSO-d6,300 MHz 1.89-1.96(2H, m) 2.40(3H, s) 2.63(2H, t, J=8.0 Hz) 2.70(2H, t, J=8.0 Hz) 6.43(2H, br. s) 6.44(1H, s) 7.16-7.40(7H, m) 7.65(1H, d, J=8.8 Hz) 7.73(1H, dd, J=2.4, 8.8 Hz) 7.95(2H, d, J=8.4 Hz) 8.37(1H, d, J=2.1 Hz) 10.28(1H, s) FAB+396 [M + H+](100)
  • TABLE 27
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    79
    Figure US20060030565A1-20060209-C00104
         		109.0-110.0° C. DMSO-d6,300 MHz 2.40(3H, s) 6.43(2H, br. s) 6.45(1H, s) 6.66(1H, d, J=12.3 Hz) 6.91(1H, d, J=12.3 Hz) 7.15-7.21(6H, m) 7.32(1H, t, J=7.2 Hz) 7.40(1H, t, J=7.2 Hz) 7.62-7.65(3H, m) 8.42(1H, s) 10.44(1H, s) FAB+380 [M + H+](100)
    80
    Figure US20060030565A1-20060209-C00105
         		124.0˜125.0° C. DMSO-d6,300 MHz 2.40(3H, s) 6.45(2H, s) 7.26-7.66(12H, m) 7.94(1H, d, J=7.9 Hz) 8.48(1H, s) 10.54(1H, s) FAB+380 [M + H+](100)
    81
    Figure US20060030565A1-20060209-C00106
         		233° C.
  • TABLE 28
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    82
    Figure US20060030565A1-20060209-C00107
         		213° C.
    83
    Figure US20060030565A1-20060209-C00108
         		DMSO-d6,300 MHz 1.30-1.62(6H, m) 2.48(2H, t, J=7.8 Hz) 2.60(3H, s) 2.77(2H, t, J=7.8 Hz) 6.61(1H, s) 7.05-7.51(9H, m) 7.92(2H, s) 8.65(2H, br. s) 8.77(1H, s) 10.77(1H, s) FAB−459 [M − H]−(5) 149 (100)
    84
    Figure US20060030565A1-20060209-C00109
         		285° C.
  • TABLE 29
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    85
    Figure US20060030565A1-20060209-C00110
         		DMSO-d6,300 MHz 2.41(3H, s) 6.45(2H, s) 6.73(2H, br. s) 6.85(1H, d, J=7.8 Hz) 7.13-7.36(13H, m) 7.58-7.72(3H, m) 8.51(1H, s) 10.55(1H, s) FAB+456 [M + H+](100)
    86
    Figure US20060030565A1-20060209-C00111
         		270.0˜273.0° C. DMSO-d6 0.81-0.85(2H, m) 1.10-1.18(5H, m) 1.43-1.68(6H, m) 2.60(3H, s) 2.79(2H, t, J=7.7 Hz) 6.62(1H, s) 7.31-7.50(4H, m) 7.95(2H, s) 8.60(2H, br. s) 8.77(1H, s) 10.77(1H, s) 13.96(1H, br. s) FAB−423 [M − H+](13)
    87
    Figure US20060030565A1-20060209-C00112
         		>300° C. DMSO-d6,300 MHz
  • TABLE 30
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    88
    Figure US20060030565A1-20060209-C00113
         		240° C.
    89
    Figure US20060030565A1-20060209-C00114
         		245.9° C. DMSO-d6,300 MHz 1.10(3H, t, J=7.6 Hz) 2.50(2H, q, J=7.6 Hz) 2.60(3H, s) 5.41(2H, s) 6.62(1H, s) 7.08(2H, s) 7.22(1H, s) 7.50-7.74(4H, m) 7.94-8.02(2H, m) 8.68(2H, br. s) 8.76(1H, s) FAB−481 [M − H]−(3) 480 (4) 155 (100)
    90
    Figure US20060030565A1-20060209-C00115
         		137.0˜138.0° C. DMSO-d6 1.10(3H, t, J=7.6 Hz) 1.30(3H, t, J=7.6 Hz) 2.49(2H, q, J=7.6 Hz) 2.84(2H, q, J=7.6 Hz) 5.40(2H, s) 6.62(1H, s) 7.08(2H, s) 7.22(2H, s) 7.53-7.62(2H, m) 7.69-7.72(2H, m) 7.91(2H, s) 8.18(2H, br. s) 8.68(1H, s) 10.82(1H, s)
  • TABLE 31
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    91
    Figure US20060030565A1-20060209-C00116
         		185.0˜186.0° C. DMSO-d6 2.59(3H, s) 3.11(3H, s) 5.45(2H, s) 6.60(1H, s) 7.16(2H, d, J=8.9 Hz) 7.55-7.72(4H, m) 7.78(2H, d, J=8.9 Hz) 7.88(2H, d, J=9.0 Hz) 7.93(2H, d, J=9.0 Hz) 8.70(2H, br, s) 8.72(1H, s) 10.89(1H, s) 13.77(1H, br, s)
    92
    Figure US20060030565A1-20060209-C00117
         		269° C. DMSO-d6, 300 MHz
    93
    Figure US20060030565A1-20060209-C00118
         		233° C. DMSO-d6, 300 MHz
  • TABLE 32
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    94
    Figure US20060030565A1-20060209-C00119
         		244° C.
    95
    Figure US20060030565A1-20060209-C00120
         		DMSO-d6, 300 MHz 2.40(3H, s) 5.35(1H, d, J=11.6 Hz) 5.87(1H, d, J=17.8 Hz) 6.41(2H, br, s) 6.45(1H, s) 7.04(1H, dd, J=11.6, 17.8 Hz) 7.42-7.78(6H, m) 8.42(1H, s) 10.46(1H, s) FAB+304 [M + H+](100)
    96
    Figure US20060030565A1-20060209-C00121
         		325.0˜330.0° C.
  • TABLE 33
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    97
    Figure US20060030565A1-20060209-C00122
         		DMSO-d6, 300 MHz 2.55(3H, s) 5.51(2H, s) 6.92(1H, s) 7.11-7.15(1H, m) 7.31-7.36(2H, m) 7.51-7.71(1H, m) 7.88-7.90(2H, m) 8.18(1H, d, J=7.2 Hz) 8.63(1H, d, J=7.5 Hz) 10.64(1H, s) 12.05(1H, s) FAB+397 [M + H+](42) 174(100)
    98
    Figure US20060030565A1-20060209-C00123
         		216° C.
    99
    Figure US20060030565A1-20060209-C00124
         		221° C.
  • TABLE 34
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    100
    Figure US20060030565A1-20060209-C00125
         		208° C.
    101
    Figure US20060030565A1-20060209-C00126
         		214° C.
    102
    Figure US20060030565A1-20060209-C00127
         		274° C.
  • TABLE 35
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    103
    Figure US20060030565A1-20060209-C00128
         		DMSO-d6, 300 MHz 1.83-2.08(3H, m) 2.30-2.42(1H, m) 2.57(3H, s) 3.50-3.75(2H, m) 4.68(1H, m) 6.57(1H, s) 7.47-7.58(5H, m) 7.84-7.93(2H, m) 8.64(2H, br, s) 8.68(1H, s) 10.60(1H, s) 13.59(1H, s)
    104
    Figure US20060030565A1-20060209-C00129
         		DMSO-d6, 300 MHz 1.83-2.29(4H, m) 3.57-3.79(2H, m) 3.72(2H, s) 4.55(1H, m) 6.57(1H, s) 7.22-7.38(5H, m) 7.88-7.93(2H, m) 8.62(1H, s) 8.66(1H, br, s) 10.57(1H, s) 13.88(1H, s) FAB−423 [M − H]−(6) 127(100)
    105
    Figure US20060030565A1-20060209-C00130
         		DMSO-d6, 300 MHz 1.80-2.39(4H, m) 2.58(3H, s) 2.79-2.85(2H, m) 3.48-3.60(2H, m) 4.52-4.54(1H, m) 6.58(1H, s) 7.11-7.30(5H, m) 7.89(2H, s) 8.64(3H, br, s) 10.52(1H, s) 13.79(1H, s) FAB−437 [M − H]−(13) 127(100)
  • TABLE 36
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    106
    Figure US20060030565A1-20060209-C00131
         		DMSO-d6, 300 MHz 1.75-2.03(6H, m) 2.33(2H, t, J=6.9 Hz) 2.51-2.63(5H, m) 3.49(2H, m) 4.51-4.54(1H, m) 6.57(1H, s) 7.09-7.31(5H, m) 7.89(1H, s) 8.61(1H, s) 8.64(2H, br, s) FAB−437 [M − H]−(13) 127(100)
    107
    Figure US20060030565A1-20060209-C00132
         		CDCl3, 300 MHz 1.72-2.07(4H, m) 2.18-2.49(2H, m) 2.56-2.82(3H, m) 2.60(3H, s) 3.20-3.24(1H, m) 3.32(1H, m) 4.86(2H, br, s) 6.49(1H, s) 7.16-7.29(5H, m) 7.32(1H, dd, J=8.9, 2.3 Hz) 7.94(1H, d, J=8.9 Hz) 8.55(1H, d, J=2.3 Hz) 9.70(1H, s) FAB+389 [M + H]+(100)
    108
    Figure US20060030565A1-20060209-C00133
         		219° C. DMSO-d6, 300 MHz
  • TABLE 37
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    109
    Figure US20060030565A1-20060209-C00134
         		DMSO-d6, 300 MHz 2.60(3H, s) 5.46(2H, s) 6.61(1H, s) 7.07(2H, dd, J=7.2, 2.4 Hz) 7.35(2H, dd, J=7.2, 2.4 Hz) 7.40(1H, d, J=2.4 Hz) 7.87(1H, d, J=2.4 Hz) 8.60-8.80(2H, brs) 8.71(1H, s) 10.57(1H, s) 14.04(1H, s)
    110
    Figure US20060030565A1-20060209-C00135
         		DMSO-d6, 300 MHz 2.60(3H, s) 4.28(2H, t-like) 4.75(2H, t-like) 6.17(1H, m) 6.62(1H, s) 6.92(2H, d, J=9.0 Hz) 7.18-7.30(4H, m) 7.98(1H, d, J=9.1 Hz) 8.05(1H, d, J=9.1 Hz) 8.40-8.90(2H, brs) 8.64(1H, s) 10.32(1H, s) 14.18(1H, s)
    111
    Figure US20060030565A1-20060209-C00136
         		DMSO-d6, 300 MHz 2.61(3H, s) 5.42(2H, s) 6.65(1H, s) 6.83(1H, d, J=1.7 Hz) 7.04(2H, d, J=8.9 Hz) 7.35(2H, d, J=8.9 Hz) 7.99(1H, d, J=1.7 Hz) 8.50-9.00(2H, brs) 8.73(1H, s) 10.73(1H, s) 14.4(1H, s)
  • TABLE 38
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    112
    Figure US20060030565A1-20060209-C00137
         		DMSO-d6, 300 MHz 2.40(3H, s) 5.57(2H, s) 6.44(1H, s) 6.48(2H, s) 7.12(2H, d, J=7.2 Hz) 7.37(2H, d, J=7.2 Hz) 7.65(1H, d, J=8.8 Hz) 7.85(1H, d, J=8.8 Hz) 8.39(1H, s) 8.69(1H, s) 10.30(1H, s)
    113
    Figure US20060030565A1-20060209-C00138
         		216° C.
    114
    Figure US20060030565A1-20060209-C00139
         		211° C.
  • TABLE 39
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    115
    Figure US20060030565A1-20060209-C00140
         		253° C.
    116
    Figure US20060030565A1-20060209-C00141
         		DMSO-d6, 300 MHz 1.67(4H, brs) 2.22(2H, brs) 2.37(2H, brs) 2.58(3H, s) 4.61(2H, s) 6.59(1H, s) 6.88-6.92(3H, m) 7.21-7.28(2H, m) 7.88(2H, s) 8.62(2H, brs) 8.68(1H, s) 10.45(1H, s) 13.85(1H, s)
    117
    Figure US20060030565A1-20060209-C00142
         		284° C. DMSO-d6, 300 MHz
  • TABLE. 40
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    118
    Figure US20060030565A1-20060209-C00143
         		CD3OD, 300 MHz 2.67(3H, s) 3.39(6H, s) 5.32(2H, s) 6.79(1H, s) 6.84-6.90(3H, m) 7.13-7.19(2H, m) 7.48-7.67(4H, m) 7.75(1H, d, J=9.0 Hz) 7.91(1H, dd, J=2.0, 9.0 Hz) 8.95(1H, s) FAB−447 [M − H+](28)
    119
    Figure US20060030565A1-20060209-C00144
         		219° C. DMSO-d6, 300 MHz 1.09(3H, t, J=7.5 Hz) 2.47(2H, q, J=7.5 Hz) 5.30(2H, s) 6.78(1H, d, J=6.9 Hz) 6.84(2H, d, J=8.7 Hz) 7.03(2H, d, J=8.7 Hz) 7.90-7.99(2H, m) 8.36(1H, br, t) 8.79(1H, s) 8.90(2H, br, s) 10.89(1H, s) 13.89(1H, s)
    120
    Figure US20060030565A1-20060209-C00145
         		231° C. DMSO-d6, 300 MHz 5.34(2H, s) 6.79(1H, d, J=6.8 Hz) 6.96(2H, d, J=6.9 Hz) 7.26(2H, d, J=6.9 Hz) 7.50-7.71(4H, m) 7.93-8.00(2H, m) 8.35(1H, d, J=6.8 Hz) 8.78(1H, s) 8.88(2H, br, s) 10.90(1H, s) 14.03(1H, s)
  • TABLE 41
    Exp.
    No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    121
    Figure US20060030565A1-20060209-C00146
         		276° C. DMSO-d6, 300 MHz 2.60 (3H, s) 3.26 (3H, s) 4.39 (2H, s) 6.57 (2H, s) 5.34 (2H, s) 6.61 (1H, s) 6.92 (2H, d, J = 8.5Hz) 7.20 (2H, d, J = 8.5Hz) 7.47-7.70 (4H, m) 7.95 (2H, s) 8.61 (2H, br.s) 8.75 (1H, s) FAB−492 [M − H]−(100)
    122
    Figure US20060030565A1-20060209-C00147
         		116.0˜117.0° C. DMSO-d6 5.34 (2H, s) 6.90-6.95 (3H, m) 7.19-7.26 (3H, m) 7.52-7.71 (5H, m) 7.93-7.97 (2H, m) 8.94 (1H, s) 9.05 (1H, br.s) 11.0 (1H, s) 13.4 (1H, br.s) FAB−405 [M − H+] (6)
    123
    Figure US20060030565A1-20060209-C00148
         		283° C. DMSO-d6, 300 MHZ
  • TABLE 42
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    124
    Figure US20060030565A1-20060209-C00149
         		164.0˜165.0° C. DMSO-d6 2.21 (2H, t, J = 7.3Hz) 2.89 (2H, t, J = 7.3Hz) 3.18 (2H, t, J = 7.3Hz) 5.35 (2H, s) 6.97 (2H, d, J = 9.0Hz) 7.27 (2H, d, J = 9.0Hz) 7.50-7.71 (4H, m) 7.86-7.89 (2H, m) 8.45 (2H, br.s) 8.76 (1H, s) 10.83 (1H, s) 14.24 (1H, br.s) FAB−479 [M − H+] (3)
    125
    Figure US20060030565A1-20060209-C00150
         		190.0˜191.0° C. DMSO-d6 5.31 (2H, s) 6.87-6.93 (3H, m) 7.09 (1H, d, J = 9.2Hz) 7.20-7.25(2H, m) 7.48-7.64 (4H, m) 7.69 (1H, d, J = 9.2Hz) 7.94 (1H, d, J = 9.2Hz) 8.38 (1H, d, J = 9.2Hz) 8.41 (1H, s) 10.78 (1H, s) 14.11 (1H, br.s)
    126
    Figure US20060030565A1-20060209-C00151
         		172.0˜173.0° C. DMSO-d6, 300MHz 2.88 (3H, d, J = 4.8Hz) 5.31 (2H,s) 6.73 (1H, d, J = 8.8Hz) 6.88-6.96 (4H, m) 7.21-7.27 (2H, m) 7.46-7.56 (3H, m) 7.62-7.68 (3H, m) 7.78 (3H, d, J = 8.8Hz) 8.11 (1H, d, J = 2.2Hz) 10.42 (1H, s) FAB+384 [M + H+](100)
  • TABLE 43
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    127
    Figure US20060030565A1-20060209-C00152
         		153.0˜155.0° C. DMSO-d6, 300MHz 1.68-2.09 (2H, m) 2.39 (3H, s) 2.31-2.56 (2H, m) 2.73-2.98 (3H, m) 4.21-4.34 (1H, m) 5.25 (2H, dd, J = 8.9Hz, J = 12.5Hz) 6.50 (1H, s) 6.99 (2H, d, J = 8.9Hz) 7.33 (2H, d, J = 8.9Hz) 7.42-7.57 (4H, m) 7.90-8.14 (2H, m) 8.60 (1H, d, J = 7.6Hz) 13.10 (1H, s) FAB−457 [M − H+](58)
    128
    Figure US20060030565A1-20060209-C00153
         		DMSO-d6, 300MHz 5.34 (2H, s) 6.85-6.94 (3H, m) 7.18-7.25 (2H, m) 7.50-7.61 (4H, m) 8.06 (1H, d, J = 8.7Hz) 8.11 8.63 (1H, J = 1.8Hz) 8.84 (1H, d, J = 1.8Hz) 8.91 (1H, d, J = 1.8Hz) 10.97 (1H, s)
    129
    Figure US20060030565A1-20060209-C00154
         		191° C.
  • TABLE 44
    Exp. No. Structural formula/character (solvent) m.p. 1H NMR (δ) ppm MS
    130
    Figure US20060030565A1-20060209-C00155
         		237° C.
    131
    Figure US20060030565A1-20060209-C00156
         		201° C.
    132
    Figure US20060030565A1-20060209-C00157
         		241° C.
  • The method for evaluating the analgesic effect of the compound of the present invention is explained in the following.
  • For in vitro evaluation, ORL-1 receptor binding assay was performed, and μ receptor binding assay was performed for the evaluation of selectivity. For in vivo evaluation, hot plate test and tail flick test known for long as a test method for analgesic effect were performed, and tactile sensation stimulating test was performed using allodynia model for evaluation of allodynia.
    • Experimental Example [1] ORL-1 Receptor Binding Assay
  • A cell membrane suspension obtained from human ORL-1 expression cells was adjusted with Tris buffer [50 mM Tris, 2 mM EDTA, 0.1 mM (p-Amidinophenyl)methanesulfonyl Fluoride Hydrochloride (p-APMSF), 2 mg/ml BSA] to membrane protein amount of about 25 μg/ml (2.5 μg/well). This was mixed with [3H]nociceptin (diluted with Tris buffer to a final concentration of 0.5 nM) and test compound (diluted with Tris buffer to a final concentration of 10 nM-10 μM), and the mixture was incubated at room temperature for 60 min. The membrane was recovered on a G/F-B filter (Packard, Unifilter 96GF/B) using a cell harvester and the reaction was stopped. After washing 3 times, the filter was dried at 42° C. for 1 hr. A scintillation solution (Packard, microscint-20) was added and the radioactivity (Packard, Top count A9912V) was assayed.
  • The nonspecific binding was the binding in the presence of 1 μM nociceptin and the difference between the total binding and nonspecific binding was taken as the specific binding. IC50 was calculated from inhibition of specific binding at each concentration of the compound, and Ki value of the test compound was calculated from this value and Kd value of [3H]nociceptin.
    • Experimental Example [2] μ Receptor Binding Assay
  • Rat cerebrum membrane standard sample (final concentration 0.755 mg, protein/ml), [3H]DAMGO (Try-D-Ala-Gly-NMe-Phe-Gly-ol) [diluted with Tris buffer (50 mM Tris-HCl, 0.1 mM p-APMSF, 2 mg/ml BSA (pH=7.4)) to a final concentration of 1 nM] and test compound (diluted with Tris buffer to a final concentration of 10 nM-10 μM) were mixed, and the mixture was incubated at room temperature for 90 min. The membrane was recovered on a G/F-B filter (same as above) using a cell harvester and the reaction was stopped. After washing 3 times, the filter was dried at 42° C. for 1 hr. A scintillation solution (same as above) was added and the radioactivity (same as above) was assayed.
  • The nonspecific binding was the binding in the presence of 10 μM naloxone and the difference between the total binding and nonspecific binding was taken as the specific binding. IC50 was calculated from inhibition of specific binding at each concentration of the compound, and Ki value of the test compound was calculated from this value and Kd value of [3H]DAMGO.
    • Experimental Example [3] Hot-Plate Test
  • Mice (Crj, ICR, 4-week-old, male) were placed on a hot-plate (temperature 55.5±0.5° C.) and the time until the mice jumped and tried to run away was recorded. The mice were grouped according to the time and body weight so that the groups were evenly membered. The test compound was suspended in a 0.5% methylcellulose (MC) solution and orally administered to mice. After 60 min, the mice were again placed on a hot-plate and the time until they licked the hindlimb or jumped and tried to run away was recorded. The significant difference from the group administered with solvent was analyzed with ANOVA followed by Dunnett two-tailed test.
    • Experimental Example [4] Tail-Flick Test
  • Rats (Crj, SD, 7 or 8-week-old, male) were irradiated with thermal beam at around the base of the tail from below and the time until the rats moved the tail and ran away was measured using a tail-flick analgesic effect measurement device (maufactured by UGO BASILE). Before the administration of the test compound, the measurement was repeated 3 times and the rats were grouped according to the time and body weight so that the groups were evenly membered. The test compound was suspended in a 0.5% MC solution and orally administered to rats. After 30, 60, 90, 120 and 180 minutes from administration, the same measurement was repeated. The significant difference from the group administered with solvent was analyzed with ANOVA followed by Dunnett two-tailed test.
    • Experimental Example [5] Allodynia Test
  • Mice (Crj, ICR, 4-week-old, male) were intrathecally administered with nociceptin (50 pg/5 μl) without anesthesia. For 20 min after administration and at 5 min intervals, an area from lateral region to tail of the mice was rubbed with a brush and the response of the mice was observed. The evaluation followed the criteria of 0; no change, 1; run or cry upon tactile stimulation, and 2; cry loud or dash away upon tactile stimulation. The test compound was suspended in a 0.5% MC solution and orally administered 60 min before nociceptin administration. The significant difference of the score of each administration group at 20 min after nociceptin administration from the group administered with solvent was analyzed with Mann-Whitny U-test.
  • The results of Experimental Examples [1] to [5] are shown in Tables 45-47.
    TABLE 45
    ORL-1 binding μ binding Allodynia Hot-plate
    Example IC50 Ki IC50 Ki M.E.D. M.E.D.
    No. (μM) (μM) (μM) (μM) (mg/kg) (mg/kg)
    1 0.12 0.007 1.52 0.570 0.3 1
    2 0.07 0.004 1.33 0.497 0.3 1
    3 1.47 0.079 1.11 0.417 3 30
    4 0.23 0.013 1.26 0.453 <1 <3
    5 0.52 0.028 1.34 0.505 3
    7 0.06 0.003 0.96 0.346 0.3 3
    8 0.94 0.050 0.49 0.183 3
    9 0.32 0.016 2.03 0.764 1 <3
    10 1.02 0.053 0.86 0.324 3
    11 0.06 0.003 1.12 0.424 0.3 3
    12 0.16 0.008 0.67 0.254 0.3 3
    16 0.11 0.006 0.69 0.259 0.1 3
    17 0.13 0.007 1.02 0.385 0.3 1

    M.E.D.: minimum effective dose
  • TABLE 46
    ORL-1 binding μ binding Allodynia Hot-plate
    Example IC50 Ki IC50 Ki M.E.D. M.E.D.
    No. (μM) (μM) (μM) (μM) (mg/kg) (mg/kg)
    18 0.09 0.004 1.04 0.393 0.3
    19 0.16 0.009 1.03 0.388 0.1 3
    25 0.15 0.008 1.18 0.464 0.3<
    26 0.08 0.004 1.22 0.479 0.3 1
    27 0.29 0.015 1.06 0.414 0.3
    29 0.16 0.009 1.05 0.414 0.3< 3
    32 0.09 0.005 0.58 0.227 0.3< —
    33 0.09 0.005 1.44 0.565 0.3
    34 0.14 0.008 2.37 0.888 0.3 3
    38 0.09 0.005 2.67 1.021 0.3<
    42 0.08 0.004 1.99 0.745 0.3 1
    43 0.11 0.005 2.10 0.785 0.3 1
    49 0.04 0.002 1.26 0.464 0.3 1

    M.E.D.: minimum effective dose
  • TABLE 47
    ORL-1 binding μ binding Allodynia Hot-plate
    Example IC50 Ki IC50 Ki M.E.D. M.E.D.
    No. (μM) (μM) (μM) (μM) (mg/kg) (mg/kg)
    51 0.17 0.008 1.40 0.525
    61 1.22 0.063 5.35 2.012 3 
    62 2.36 0.125 2.00 0.783 3<
    63 1.03 0.054 1.42 0.545 3<
    64 1.39 0.073 3.61 1.382 3<
    65 1.16 0.064 3<
    66 2.00 0.108 3<
    71 1.77 0.089 30 
    84 2.52 0.129 1.11 0.419 <3  10<
    89 0.13 0.006 1.46 0.548  0.3 1
    90 0.11 0.005 1.18 0.442 — 3
    93 0.12 0.007   0.3< —

    M.E.D.: minimum effective dose
  • As is evident from the above test results, the compound of the present invention shows strong analgesic effect due to nociceptin antagonistic action, and a part thereof shows selective action on ORL-1 receptors as compared to opioid receptors (μ, κ, δ receptors) including μ receptor.
  • Hence, the inventive compound can make a pharmaceutical agent effective against pain, particularly strong pain such as postoperative pain and the like or pain caused by sensory nerve abnormality such as hyperalgesia, allodynia and the like. In addition, since the compound shows selective action on ORL-1 receptor, it can be a safe pharmaceutical agent without marked side effects.
  • This application is based on application No. 100029/1998 filed in Japan, the content of which is incorporated hereinto by reference.

Claims (20)

1. A nociceptin antagonist containing an amide derivative of the formula [1]
Figure US20060030565A1-20060209-C00158
wherein
R1 and R2 are the same or different and each is hydrogen atom, lower alkyl optionally substituted by hydroxy, amino, lower alkylamino or di(lower)alkylamino;
R3 and R4 are the same or different and each is hydrogen atom, halogen atom or-lower alkyl;
ring A is aryl or heterocyclic group;
ring B is phenyl, thienyl, furyl, pyrrolyl, pyrrolidinyl, oxazolyl or cyclohexenyl; and
X is hydrogen atom, halogen atom, lower alkyl optionally substituted by lower alkoxy, lower alkenyl, amino, cyano or a group of the formula
Figure US20060030565A1-20060209-C00159
wherein E is a single bond, carbonyl, sulfinyl,
—O—, —S—, —NHCO—, —CH═CR6— wherein R6 is hydrogen atom or aryl or —NR7— wherein R7 is hydrogen atom, lower alkyl or lower alkoxycarbonyl;
ring G is aryl, heterocyclic group, cycloalkyl or condensed aryl;
R5 is halogen atom, hydroxy, lower alkyl Optionally substituted by any of halogen atom, hydroxy, lower alkanoyloxy and lower alkoxy optionally substituted by lower alkoxy, lower alkoxy optionally substituted by lower alkoxy, amino, lower alkylamino, di(lower)alkylamino, nitro, cyano, lower alkanoyl, lower alkanoyloxy, carboxy, lower alkoxycarbonyl, lower alkylsulfonyl or phenyl;
t is 0 or an integer of 1 to 5, which indicates the number of substituents on the ring G,
wherein when t is an integer of 2 to 5, each R5 may be the same or different;
m is 0 or an integer of 1 to 8; and
n is 0 or an integer of 1 to 4, or a pharmaceutically acceptable salt thereof as an active ingredient.
2. A nociceptin antagonist containing the amide derivative of claim 1, wherein the ring A is quinolyl or a pharmaceutically acceptable salt thereof as an active ingredient.
3. A nociceptin antagonist containing the amide derivative of claim 1, wherein the ring B is phenyl and X is a group of the formula
Figure US20060030565A1-20060209-C00160
wherein E, ring G, R5, t, m and n are as defined in claim 1, or a pharmaceutically acceptable salt thereof as an active ingredient.
4. A nociceptin antagonist containing the amide derivative of claim 3, wherein the ring A is
Figure US20060030565A1-20060209-C00161
wherein R8 is lower alkylthio, or a pharmaceutically acceptable salt thereof as an active ingredient.
5. An amide derivative of the formula [1′]
Figure US20060030565A1-20060209-C00162
wherein R2, ring B, E, ring G, R5, t, m and n as defined in claim 1, or a pharmaceutically acceptable salt thereof.
6. The amide derivative of claim 5, wherein the ring B is phenyl and R2 is lower alkyl, or a pharmaceutically acceptable salt thereof.
7. The amide derivative of claim 6, wherein the amino substitutes at the 4-position on a quinoline skeleton, R2 is methyl substituting at the 2-position on the quinoline skeleton, E is —O— and the ring B of phenyl has a substituent of the formula
Figure US20060030565A1-20060209-C00163
wherein ring G, R5, t, m and n as defined in claim 1, at the 2-position, or a pharmaceutically acceptable salt thereof.
8. The amide derivative of claim 7 or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-ethylphenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(2,4-dichlorophenoxy)-methyl]benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-(phenoxymethyl)benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-methoxyphenoxy)-methyl]benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(3,5-dimethylphenoxy)-methyl]benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(3,4-dimethoxyphenoxy)-methyl]benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-nitrophenoxy)methyl]-benzamide,
N-(4-amino-2-methyl-6-quinolyl)-2-[(2,3-dimethoxyphenoxy)-methyl]benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(3-methylphenoxy)-methyl]benzamide,
N-(4-amino-2-methyl-6-quinolyl)-2-[(3,5-dimethoxyphenoxy)-methyl]benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-chlorophenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-acetylphenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-hydroxyphenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-methoxymethoxyphenoxy)-methyl]benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(3-methoxyphenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-cyanophenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-methylphenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-trifluoromethylphenoxy)methyl]benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(3-nitrophenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(2-nitrophenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-acetoxyphenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(2-methoxyphenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-aminophenoxy)methyl]-benzamide dihydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[-(3-chlorophenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-fluorophenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(3,4-dichlorophenoxy)-methyl]benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(2-chlorophenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-dimethylaminophenoxy)-methyl]benzamide dihydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-tert-butylphenoxy)-methyl]benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-(4-biphenylyloxymethyl)-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-isopropylphenoxy)-methyl]benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-nitrophenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-bromophenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-propylphenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(3-fluorophenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(3-trifluoromethylphenoxy)methyl]benzamide hydrochloride,
methyl 4-[2-{N-(4-amino-2-methyl-6-quinolyl)carbamoyl}-benzyloxylbenzoate hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-iodophenoxy)methyl]-benzamide,
N-(4-amino-2-methyl-6-quinolyl)-2-(3-pyridyloxymethyl)-benzamide hydrochloride,
4-[2-{(4-amino-2-methyl-6-quinolyl)carbamoyl}benzyloxy]-benzoate hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(3-cyanophenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-mesylphenoxy)methyl]-benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(2-chloro-4-ethylphenoxy)-methyl]benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-chloro-3-methylphenoxy)methyl]benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(2-chloro-4-methylphenoxy)methyl]benzamide hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-ethylphenoxy)methyl]-benzamide,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-chloro-3-methylphenoxy)methyl]benzamide,
4-[2-{(4-amino-2-methyl-6-quinolyl)carbamoyl}benzyloxy]benzyl acetate hydrochloride,
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-hydroxymethylphenoxy)-methyl]benzamide hydrochloride and
N-(4-amino-2-methyl-6-quinolyl)-2-[(4-ethylphenoxy)methyl]-benzamide hydrochloride monohydrate.
9. An amide derivative of the formula [1″]
Figure US20060030565A1-20060209-C00164
wherein the ring A, R2, R5 and t are as defined in claim 1, or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition comprising the amide derivative of any of claims 5 to 9 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
11. A nociceptin antagonist containing the amide derivative of any of claims 5 to 9 or a pharmaceutically acceptable salt thereof as an active ingredient.
12. An analgesic containing the amide derivative of any of claims 1 to 9 or a pharmaceutically acceptable salt thereof as an active ingredient.
13. A method for expressing a nociceptin antagonistic action, comprising administering the amide derivative of any of claims 1 to 9 or a pharmaceutically acceptable salt thereof.
14. A method for treating pain, comprising administering the amide derivative of any of claims 1 to 9 or a pharmaceutically acceptable salt thereof.
15. Use of the amide derivative of any of claims 1 to 9 or a pharmaceutically acceptable salt thereof for the production of a nociceptin antagonist.
16. Use of the amide derivative of any of claims 1 to 9 or a pharmaceutically acceptable salt thereof for the production of an analgesic.
17. A pharmaceutical composition for antagonizing nociceptin, which comprises the amide derivative of any of claims 1 to 9 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
18. A commercial package comprising the pharmaceutical composition of claim 17 and a written matter associated therewith, the written matter stating that the pharmaceutical composition can be or should be used for antagonizing nociceptin.
19. A pharmaceutical composition for analgesic use, which comprises the amide derivative of any of claims 1 to 9 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
20. A commercial package comprising the pharmaceutical composition of claim 19 and a written matter associated therewith, the written matter stating that the pharmaceutical composition can be or should be used for analgesia.
US11/145,169 1998-03-26 2005-06-06 Amide derivatives and nociceptin antagonists Abandoned US20060030565A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/145,169 US20060030565A1 (en) 1998-03-26 2005-06-06 Amide derivatives and nociceptin antagonists

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP100029/1998 1998-03-26
JP10002998 1998-03-26
US09/646,781 US6410561B1 (en) 1998-03-26 1999-03-23 Amide derivatives and nociceptin antagonists
PCT/JP1999/001462 WO1999048492A1 (en) 1998-03-26 1999-03-23 Amide derivatives and nociceptin antagonists
US10/141,866 US6903094B2 (en) 1998-03-26 2002-05-10 Amide derivatives and nociceptin antagonists
US11/145,169 US20060030565A1 (en) 1998-03-26 2005-06-06 Amide derivatives and nociceptin antagonists

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/141,866 Division US6903094B2 (en) 1998-03-26 2002-05-10 Amide derivatives and nociceptin antagonists

Publications (1)

Publication Number Publication Date
US20060030565A1 true US20060030565A1 (en) 2006-02-09

Family

ID=14263120

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/646,781 Expired - Fee Related US6410561B1 (en) 1998-03-26 1999-03-23 Amide derivatives and nociceptin antagonists
US10/141,866 Expired - Fee Related US6903094B2 (en) 1998-03-26 2002-05-10 Amide derivatives and nociceptin antagonists
US11/145,169 Abandoned US20060030565A1 (en) 1998-03-26 2005-06-06 Amide derivatives and nociceptin antagonists

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/646,781 Expired - Fee Related US6410561B1 (en) 1998-03-26 1999-03-23 Amide derivatives and nociceptin antagonists
US10/141,866 Expired - Fee Related US6903094B2 (en) 1998-03-26 2002-05-10 Amide derivatives and nociceptin antagonists

Country Status (21)

Country Link
US (3) US6410561B1 (en)
EP (1) EP1072263A4 (en)
KR (1) KR20010042161A (en)
CN (1) CN1301154A (en)
AR (1) AR018168A1 (en)
AU (1) AU754716B2 (en)
BR (1) BR9909666A (en)
CA (1) CA2325638A1 (en)
CO (1) CO5080780A1 (en)
FI (1) FI20002103A (en)
HU (1) HUP0101275A3 (en)
ID (1) ID26099A (en)
IL (1) IL138573A0 (en)
NO (1) NO20004778L (en)
NZ (1) NZ507760A (en)
RU (1) RU2202344C2 (en)
SK (1) SK14272000A3 (en)
TR (1) TR200003598T2 (en)
TW (1) TW487571B (en)
WO (1) WO1999048492A1 (en)
ZA (1) ZA200005881B (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030134331A1 (en) * 2000-05-10 2003-07-17 The Trustees Of Columbia University Controlling pathways that regulate muscle contraction in the heart
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US20050187386A1 (en) * 2002-11-05 2005-08-25 Andrew Robert Marks Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US20050186640A1 (en) * 2000-05-10 2005-08-25 Marks Andrew R. Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RYR2)
US20050215540A1 (en) * 2004-01-22 2005-09-29 Marks Andrew R Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US20070049572A1 (en) * 2005-08-25 2007-03-01 The Trustees Of Columbia University In The City Of New York Novel agents for preventing and treating disorders involving modulation of the RyR receptors
US20070173482A1 (en) * 2005-08-25 2007-07-26 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20110172190A1 (en) * 2004-01-22 2011-07-14 Andrew Robert Marks Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8722731B2 (en) 2010-06-07 2014-05-13 Novomedix, Llc Furanyl compounds and the use thereof
WO2016003886A1 (en) * 2014-07-02 2016-01-07 Lam Therapeutics, Inc. 4-aminoquinoline compositions and methods for using same

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1182193A4 (en) 1999-04-09 2002-09-11 Mochida Pharm Co Ltd Remedies for neuropathic pain
JP3989247B2 (en) 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． Triazospiro compounds having affinity for nociceptin receptor
WO2001039775A1 (en) 1999-12-06 2001-06-07 Euro-Celtique, S.A. Benzimidazole compounds having nociceptin receptor affinity
EP1244437A4 (en) 1999-12-06 2005-02-09 Euro Celtique Sa Tertiary amino compounds having opioid receptor affinity
DE19963175A1 (en) * 1999-12-27 2001-07-12 Gruenenthal Gmbh Use of substituted 4-amino-1-phenylbutan-2-ol compounds as medicaments
CN1242993C (en) * 2000-03-31 2006-02-22 日本新药株式会社 Heterocycle derivatives and drugs
US7312044B2 (en) 2003-03-07 2007-12-25 The Trustees Of Columbia University In The City Of New York Type 1 ryanodine receptor-based methods
HUP0301094A2 (en) * 2000-09-15 2003-09-29 Anormed Inc. Chemokine receptor binding heterocyclic compounds, pharmaceutical compositions containing this compounds and their use
WO2002026714A1 (en) * 2000-09-27 2002-04-04 Takeda Chemical Industries, Ltd. Spiro compounds
SE0004053D0 (en) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
SE0004054D0 (en) 2000-11-06 2000-11-06 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
EP1342717A4 (en) 2000-11-15 2005-02-16 Banyu Pharma Co Ltd Benzimidazole derivatives
JP2002241311A (en) * 2000-12-12 2002-08-28 Japan Tobacco Inc Surfactant-containing pharmaceutical composition
RU2003130752A (en) * 2001-03-19 2005-03-10 Ниппон Синяку Ко., Лтд. (Jp) ANTIPROSIONAL AGENTS
EP2033644A1 (en) 2001-04-18 2009-03-11 Euro-Celtique S.A. Spiroindene and spiroindane compounds
MXPA03009602A (en) 2001-04-18 2004-04-02 Euro Celtique Sa Nociceptin analogs.
ATE456564T1 (en) 2001-04-18 2010-02-15 Euro Celtique Sa OCTAHYDROBENZIMIDAZOLONE COMPOUNDS AS ANALGESICS
PL367263A1 (en) 2001-04-18 2005-02-21 Euro-Celtique, S.A. Spiropyrazole compounds
ES2323876T3 (en) 2001-04-18 2009-07-27 Euro-Celtique S.A. DERIVATIVES OF 1- (4-PIPERIDINIL) -1,3-DIHIDRO-2H-BENZOXAZOL-2-ONA AND RELATED COMPOUNDS AS ANALOGS OF NOCICEPTINE AND LIGANDS OF ENT1 FOR THE TREATMENT OF PAIN.
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
WO2003030828A2 (en) 2001-10-09 2003-04-17 Synvax, Inc. Nociceptin-based analgesics
EP1450801A4 (en) * 2001-11-27 2010-10-27 Merck Sharp & Dohme 2-aminoquinoline compounds
US7566728B2 (en) 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
US7235558B2 (en) * 2002-06-06 2007-06-26 Sanofi-Aventis Deutschland Gmbh Inhibitors of the GPIb—vWF interaction, their preparation and use
EP1388342A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7105513B2 (en) * 2002-08-07 2006-09-12 Sanofi-Avertis Deutschland Gmbh Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
US7696225B2 (en) 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
TWI299664B (en) * 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
EP1630162A4 (en) 2003-05-21 2010-06-09 Banyu Pharma Co Ltd 2-aminoquinoline derivative
WO2005033079A1 (en) 2003-09-30 2005-04-14 Eisai Co., Ltd. Novel antifungal agent comprising heterocyclic compound
BRPI0415179A (en) 2003-10-07 2006-11-28 Renovis Inc amide derivatives such as ion channel ligands and pharmaceutical compositions and methods of employing them
CA2542329A1 (en) * 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
EP1568698A1 (en) * 2004-02-27 2005-08-31 Aventis Pharma Deutschland GmbH Pyrrole-derivatives as factor Xa inhibitors
ES2347577T3 (en) * 2004-03-12 2010-11-02 Eli Lilly And Company OPIOID RECEPTOR ANTAGONISTS.
JP5081448B2 (en) 2004-06-09 2012-11-28 株式会社カネカ Curable composition
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
EP1864980A4 (en) 2005-03-30 2010-08-18 Eisai R&D Man Co Ltd Antifungal agent containing pyridine derivative
TWI385169B (en) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd Heterocyclic substituted pyridine derivatives and antifungal agent containing same
EP1987009A1 (en) 2006-01-30 2008-11-05 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
WO2008023333A2 (en) * 2006-08-22 2008-02-28 Ranbaxy Laboratories Limited Process for the preparation of 4-(isobutylamino)-3-amino-quinoline
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
US20110034478A1 (en) * 2008-04-15 2011-02-10 Schering-Plough Corporation Oral Pharmaceutical Compositions in a Solid Dispersion Comprising Preferably Posaconazole and HPMCAs
UA104004C2 (en) 2008-07-30 2013-12-25 Пердью Фарма Л.П. Buprenorphine analogs
BR112012006859A2 (en) 2009-09-29 2019-09-24 Glaxo Group Ltd compounds
EP2608787B1 (en) 2010-08-24 2019-11-20 Idorsia Pharmaceuticals Ltd Proline sulfonamide derivatives as orexin receptor antagonists
MX2013003354A (en) 2010-09-21 2013-06-24 Purdue Pharma Lp Buprenorphine analogs.
US9458161B1 (en) 2011-11-03 2016-10-04 Vanderblit University TSPO ligands for cancer imaging and treatment
US9096606B2 (en) 2011-12-08 2015-08-04 Purdue Pharma, L.P. Quarternized buprenorphine analogs
MX359634B (en) 2011-12-21 2018-10-03 Novira Therapeutics Inc Hepatitis b antiviral agents.
JP6114382B2 (en) 2012-05-11 2017-04-12 パーデュー、ファーマ、リミテッド、パートナーシップ Benzomorphan compounds as opioid receptor modulators
KR20210081451A (en) 2012-08-28 2021-07-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
CA2890655A1 (en) 2012-11-09 2014-05-15 Purdue Pharma L.P. Benzomorphan analogs and the use thereof
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
BR112015025052A2 (en) 2013-04-03 2021-07-06 Janssen Sciences Ireland Uc n-phenyl carboxamide derivatives and their use as medicines for the treatment of hepatitis b
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9567299B2 (en) 2013-10-23 2017-02-14 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (en) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Combination therapy for treatment of hbv infections
DK3102572T3 (en) 2014-02-06 2019-02-04 Janssen Sciences Ireland Uc SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
EP3110416A4 (en) 2014-02-25 2017-07-26 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of complement mediated disorders
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
EP3139921A4 (en) 2014-05-06 2018-02-14 Purdue Pharma L.P. Benzomorphan analogs and use thereof
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
JP2018510159A (en) 2015-03-19 2018-04-12 ノヴィラ・セラピューティクス・インコーポレイテッド Azocan and azonan derivatives and methods for treating hepatitis B infection
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
AR105808A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc AMIDA COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
AR105809A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
WO2017035355A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
AR106018A1 (en) * 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US10000516B2 (en) 2015-08-26 2018-06-19 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
AU2016330964B2 (en) 2015-09-29 2021-04-01 Novira Therapeutics, Inc. Crystalline forms of a hepatitis B antiviral agent
CN105461623A (en) * 2015-12-29 2016-04-06 江苏理工学院 Synthetic method of 4-amino-6-nitro-3-bromoquinoline
MX2018012557A (en) 2016-04-15 2019-07-04 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor.
CA3029262A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
EP3589628A4 (en) 2017-03-01 2021-03-31 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
DE102017212649A1 (en) * 2017-07-24 2019-01-24 Beiersdorf Ag Use of N- (4-amino-2-methylquinolin-6-yl) -2 - ((4-ethylphenoxy) methyl) benzamide for the preparation of cosmetic or dermatological preparations for the treatment and / or prophylaxis of the symptoms of intrinsic and / or extrinsic Skin aging and the treatment and prophylaxis of the harmful effects of ultraviolet radiation on the skin
EP3661493A4 (en) 2017-08-02 2021-04-14 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
CR20200378A (en) 2018-03-14 2021-01-08 Janssen Sciences Ireland Unlimited Co Capsid assembly modulator dosing regimen
JP7538113B2 (en) 2018-08-20 2024-08-21 アキリオン ファーマシューティカルズ，インコーポレーテッド Pharmaceutical compounds for the treatment of medical disorders of complement factor D - Patents.com
JP7443375B2 (en) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ， インコーポレーテッド Macrocyclic compounds for the treatment of medical disorders
CA3111810A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of dancopan
AU2019346464A1 (en) 2018-09-25 2021-04-08 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
MA55020A (en) 2019-02-22 2021-12-29 Janssen Sciences Ireland Unlimited Co AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR DISEASES INDUCED BY HEPATITIS B VIRUS
TW202108576A (en) 2019-05-06 2021-03-01 愛爾蘭商健生科學愛爾蘭無限公司 Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
KR20220044753A (en) * 2019-07-25 2022-04-11 큐라데브 파마 프라이버트 리미티드 Small molecule inhibitor of acetyl coenzyme A synthetase short chain 2 (ACSS2)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3649637A (en) * 1967-11-03 1972-03-14 Smith & Nephew Substituted 5-(ortho carboxanilidophenoxymethyl)tetrazoles
US4293549A (en) * 1977-11-07 1981-10-06 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktion-Saktieselskab) Quinolinyl guanidines having antiinflammatory, analgesic or antipyretic activity
US4753951A (en) * 1985-10-18 1988-06-28 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives useful as psychotropic agents
US4839366A (en) * 1983-04-06 1989-06-13 Chiesi Farmaceutici S.P.A. Methylthioquinolyl guanidine derivative, process of preparation thereof and pharmaceutical compositions therefrom
US5019574A (en) * 1988-09-30 1991-05-28 Chugai Seiyaku Kabushiki Kaisha 3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function
US5104884A (en) * 1985-05-07 1992-04-14 Alkaloida Vegyeszeti Gyar Triazolyl quinoline derivatives

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE590239C (en) * 1931-08-19 1933-12-28 I G Farbenindustrie Akt Ges Process for the preparation of quaternary nodes of heterocyclic nitrogen compounds
DE947552C (en) * 1944-04-18 1956-09-06 Hoechst Ag Process for the preparation of 4-amino quinaldine compounds
JPH07620B2 (en) 1985-10-18 1995-01-11 塩野義製薬株式会社 Condensed imidazopyridine derivative
US4791112A (en) 1987-02-02 1988-12-13 The Boc Group, Inc. N-heterocyclic-N-(4-piperidyl)amides and pharmaceutical compositions and methods employing such compounds
JPH02167265A (en) 1988-09-30 1990-06-27 Chugai Pharmaceut Co Ltd Novel 3,4-diaminoquinoline and pyridine-based compound
ATE144511T1 (en) 1989-02-02 1996-11-15 Yamanouchi Pharma Co Ltd TETRAHYDROBENZIMIDAZOLE DERIVATIVES
AU638840B2 (en) * 1990-07-05 1993-07-08 Sumitomo Chemical Company, Limited Pyrimidine derivative
GB9402275D0 (en) 1994-02-07 1994-03-30 Fujisawa Pharmaceutical Co Quinoline derivatives
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
WO1996013485A1 (en) 1994-10-27 1996-05-09 Fujisawa Pharmaceutical Co., Ltd. Pyridopyrimidones, quinolines and fused n-heretocycles as bradykinin antagonists
DE69633196D1 (en) 1995-10-16 2004-09-23 Fujisawa Pharmaceutical Co HETEROCYCLIC COMPOUNDS AS H + ATPASES

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3649637A (en) * 1967-11-03 1972-03-14 Smith & Nephew Substituted 5-(ortho carboxanilidophenoxymethyl)tetrazoles
US4293549A (en) * 1977-11-07 1981-10-06 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktion-Saktieselskab) Quinolinyl guanidines having antiinflammatory, analgesic or antipyretic activity
US4839366A (en) * 1983-04-06 1989-06-13 Chiesi Farmaceutici S.P.A. Methylthioquinolyl guanidine derivative, process of preparation thereof and pharmaceutical compositions therefrom
US5104884A (en) * 1985-05-07 1992-04-14 Alkaloida Vegyeszeti Gyar Triazolyl quinoline derivatives
US4753951A (en) * 1985-10-18 1988-06-28 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives useful as psychotropic agents
US5019574A (en) * 1988-09-30 1991-05-28 Chugai Seiyaku Kabushiki Kaisha 3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030134331A1 (en) * 2000-05-10 2003-07-17 The Trustees Of Columbia University Controlling pathways that regulate muscle contraction in the heart
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US20050186640A1 (en) * 2000-05-10 2005-08-25 Marks Andrew R. Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RYR2)
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US20050187386A1 (en) * 2002-11-05 2005-08-25 Andrew Robert Marks Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US20110172190A1 (en) * 2004-01-22 2011-07-14 Andrew Robert Marks Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20050215540A1 (en) * 2004-01-22 2005-09-29 Marks Andrew R Novel anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US20070173482A1 (en) * 2005-08-25 2007-07-26 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20070049572A1 (en) * 2005-08-25 2007-03-01 The Trustees Of Columbia University In The City Of New York Novel agents for preventing and treating disorders involving modulation of the RyR receptors
US8722731B2 (en) 2010-06-07 2014-05-13 Novomedix, Llc Furanyl compounds and the use thereof
US9149527B2 (en) 2010-06-07 2015-10-06 Novomedix, Llc Furanyl compounds and the use thereof
US9663483B2 (en) 2010-06-07 2017-05-30 Novomedix, Llc Furanyl compounds and the use thereof
WO2016003886A1 (en) * 2014-07-02 2016-01-07 Lam Therapeutics, Inc. 4-aminoquinoline compositions and methods for using same

Also Published As

Publication number Publication date
ZA200005881B (en) 2001-08-23
RU2202344C2 (en) 2003-04-20
US6410561B1 (en) 2002-06-25
AU2855899A (en) 1999-10-18
ID26099A (en) 2000-11-23
TR200003598T2 (en) 2001-06-21
CN1301154A (en) 2001-06-27
FI20002103A (en) 2000-11-17
CA2325638A1 (en) 1999-09-30
HUP0101275A2 (en) 2001-09-28
HUP0101275A3 (en) 2002-12-28
WO1999048492A1 (en) 1999-09-30
US6903094B2 (en) 2005-06-07
NO20004778D0 (en) 2000-09-25
TW487571B (en) 2002-05-21
EP1072263A1 (en) 2001-01-31
BR9909666A (en) 2001-09-11
CO5080780A1 (en) 2001-09-25
NO20004778L (en) 2000-11-27
SK14272000A3 (en) 2001-05-10
AU754716B2 (en) 2002-11-21
EP1072263A4 (en) 2004-03-31
KR20010042161A (en) 2001-05-25
AR018168A1 (en) 2001-10-31
IL138573A0 (en) 2001-10-31
US20030055087A1 (en) 2003-03-20
NZ507760A (en) 2002-10-25

Similar Documents

Publication Publication Date Title
US6903094B2 (en) Amide derivatives and nociceptin antagonists
US7879863B2 (en) Aniline derivatives
US20050209213A1 (en) Quinoline compound
WO2001025228A1 (en) Amine derivatives
US20100324017A1 (en) Acylguanidine derivative
US11466012B2 (en) Tetrahydroisoquinoline compounds
US20070191447A1 (en) Novel heterocyclic compound
KR20080021134A (en) Piperazine-piperidine antagonists and agonists of the 5-ht1a receptor
US20120142727A1 (en) Nitrogenous-ring acylguanidine derivative
TW201625533A (en) KCNQ 2~5 channel activating agent
US20050222203A1 (en) Nitrogen heterocycle biaryls for osteoporosis and other diseases
JP3013989B2 (en) Amide derivatives and nociceptin antagonists
US11407760B2 (en) Dioxinoquinoline compounds, preparation method and uses thereof
US8962612B2 (en) Tetrahydroisoquinoline derivative
KR20040041092A (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
MXPA00009438A (en) Amide derivatives and nociceptin antagonists
US20060217375A1 (en) New compounds
US10800776B2 (en) Fluorine-containing triazolopyridine, and manufacturing method, pharmaceutical composition, and application thereof
JP2010527369A (en) ((Phenyl) imidazolyl) methyl heteroaryl compounds
CZ20003448A3 (en) Nociceptin antagonist, amide derivative, pharmaceutical preparation, process, use and commercial package
KR20220044721A (en) 5-Heteroaryl-pyridin-2-amine compounds as neuropeptide FF receptor antagonists
CA3181590A1 (en) Substituted isoquinolinylmethyl amides, analogues thereof, and methods using same
US20080051423A1 (en) Nitrogen heterocycle biaryls for osteoporosis and other diseases

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION